AU2006291526B2 - Combinations comprising a VEGF receptor inhibitor and a penetration enhancer - Google Patents

Combinations comprising a VEGF receptor inhibitor and a penetration enhancer Download PDF

Info

Publication number
AU2006291526B2
AU2006291526B2 AU2006291526A AU2006291526A AU2006291526B2 AU 2006291526 B2 AU2006291526 B2 AU 2006291526B2 AU 2006291526 A AU2006291526 A AU 2006291526A AU 2006291526 A AU2006291526 A AU 2006291526A AU 2006291526 B2 AU2006291526 B2 AU 2006291526B2
Authority
AU
Australia
Prior art keywords
mmol
carboxylic acid
etoac
trifluoromethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006291526A
Other versions
AU2006291526A1 (en
Inventor
Andreas Billich
Anton Stutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518671A external-priority patent/GB0518671D0/en
Priority claimed from GB0518672A external-priority patent/GB0518672D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006291526A1 publication Critical patent/AU2006291526A1/en
Application granted granted Critical
Publication of AU2006291526B2 publication Critical patent/AU2006291526B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

C NRPonblDCCR8R 01J7,6_ I DDC-KI6/20101 1 Combinations comprising a VEGF receptor inhibitor The present invention relates to combinations comprising a VEGF receptor inhibitor, e.g. together with a penetration enhancer. 5 In one aspect the present invention provides a composition comprising a VEGF receptor inhibitor and a penetration enhancer, e.g. for topical administration. In another aspect of the present invention the VEGF receptor inhibitor is a compound of formula X1,-A Y G 0 N ,B E W 1 Z ) N W"R2 Y H 10
R
1 wherein
R
1 is H; halo; -(Co.
7
)-R
3 ; -(CO.
7
)-NR
4
R
5 ; or -C(=O)-R 6 ;
R
2 is substituted (C 3
-
8 )cycloalkyl; substituted aryl; or substituted heterocyclyl;
R
3 is H or unsubstituted or substituted (C 1 .4)alkyl; 15 R 4 and R 5 are independently selected from the group consisting of H; unsubstituted or substituted (C1.4) alkyl; (C 1 .4)alkyl-carbonyl, wherein the (C 1
.
4 )alkyl moiety is optionally substituted; and (Cl. 4)alkoxy-carbonyl, wherein the (C 1 .4)alkyl moiety is optionally substituted; R6 is H; unsubstituted or substituted (C1.4) alkyl; (C 1 .4)alkoxy, wherein the (C 1
.
4 )alkyl moiety is optionally substituted; or unsubstituted, mono- or di-substituted amino; 20 A, B and X are independently selected from =C(R 7 )- or N; E, G and T are independently selected from =C(R 8 )- or N;
R
7 and R 8 are independently selected from the group consisting of H, halo and unsubstituted or substituted (C 1 .4)alkyl; Y is -0-, -S-, -S(O)-, -S(O) 2 -, -CH 2 - or -CH 2
-CH
2 -; 25 Z is CH or N and 0 is (C 1
.
4 )alkylene or (C 2
.
4 )alkylene, wherein (C 1 .4)alkylene or (C 2 -4)alkenylene optionally may be substituted and wherein one or more of the carbon atoms of said (C1. 4)alkylene or (C 2 -4)alkenylene chain optionally may be replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur; and the bond between Q and Z characterized by a dotted line is a single bond; with the proviso that if Z is N, Q is not unsubstituted unbranched 30 (C 1
.
4 )alkylene; or Z is C and Q is as defined above wherein the bond between Q and Z characterized by a dotted line is a double bond; and W is either not present or (C1 -3)alkylene; 35 or a tautomer thereof, or in the form of a salt, a solvate or in the form of a salt and a solvate, and wherein the penetration enhancer is selected from the group consisting of unsaturated fatty acids, C NRPor\DCCVRBR0M 06_I DOC-/l6/2010 2 unsaturated fatty acid esters and unsaturated fatty acid alcohols. If not defined otherwise - Alkyl includes (C 1
.
7 )alkyl, which may be branched or straight-chained, such as e.g. n-pentyl, n 5 hexyl or n-heptyl or preferably (C 1 .4)alkyl, such as methyl, ethyl, n-propyl, sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl. - The term "(Co.7)" is as defined above for alkyl with the difference that in case of "Co." no carbon atom is present. 10 - Substituted (C 1
.
7 )alkyl or a substituted (C 1
.
7 )alkyl moiety is a (C 1
.
7 )alkyl radical/moiety substituted by one or more, preferably one, substituent, selected independently from e.g. amino, N-(C 1 . 7 )alkylamino, N,N-di-(C 1
.
7 )alkylamino, N-(C 1
.
7 )alkanoylamino, N,N-di-(C 1
.
7 )alkanoylamino, hydroxy,
(C
1
.
7 )alkoxy, (C1.
7 )alkanoyl, (C 1 .7)alkanoyloxy, cyano, nitro, carboxy, (C 1
.
7 )alkoxycarbonyl, 15 carbamoyl, N-(C 1 .7)alkyl-carbamoyl, N,N-di-(C 1
.
7 )alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, (C 1
.
7 )alkylthio, halo, or unsubstituted or substituted heterocyclyl.
WO 2007/031265 PCT/EP2006/008857 3 - (C 1 .4)alkylene and (C 2 .4)alkenylene may be branched or unbranched and are in particular (C 2 3 )alkylene and (C 2
-
3 )alkenylene, respectively. In optionally substituted (C 1 .4)alkylene or (C 2 4 )alkenylene, the substituents are e.g. selected from amino, N-(C 1
.
7 )alkylamino, N,N-di-(C 1 . 5 7 )alkylamino, N-(C 1
.
7 )alkanoylamino, N,N-di-(C 1
.
7 )alkanoylamino, hydroxy, (C1.
7 )alkoxy, (C1. 7 )alkanoyl, (C 1
.
7 )alkanoyloxy, cyano, nitro, carboxy, (C 1
.
7 )alkoxycarbonyl, carbamoyl, N-(C 1
.
7 )alkyl carbamoyl, N,N-di-(C 1
.
7 )alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, (C 1
.
7 )alkylthio and halo, or (C 1
.
7 )alkyl substituted by one or more, preferably one, of said substituents. 10 - Mono- or di-substituted amino is amino substituted by one or two radicals selected independently of one another from e.g. substituted and especially unsubstituted lower alkyl. - Substituted (C.)cycloalkyl is especially cyclohexyl and is preferably substituted as described for substituted aryl. 15 - Substituted aryl is preferably an aromatic radical with 4 to 8 carbon atoms, especially phenyl, wherein said radical is substituted by one or more, preferably by one or two, radicals such as e.g. unsubstituted or substituted (C1.
7 )alkyl, amino, N-(Cl- 7 )alkylamino, N,N-di-(C 1
.
7 )alkylamino, N-(C 1 . 7 )alkanoylamino, N,N-di-(Cl-)alkanoylamino, hydroxy, (C1.
7 )alkoxy, (C 4)alkanoyl, (C 1 . 20 7 )alkanoyloxy, cyano, nitro, carboxy, (Cl- 7 )alkoxycarbonyl, carbamoyl, N-(C 1
.
7 )alkyl-carbamoyl, N,N-di-(Cl- 7 )alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, (Cl.
7 )alkylthio, halo, or unsubstituted or substituted heterocyclyl. - Unsubstituted or substituted heterocyclyl is preferably a saturated, partially saturated or 25 unsaturated mono- or bicyclic radical having from 4 to 8 ring members and from 1 to 3 heteroatoms which are preferably selected from N, 0, S, said radical being unsubstituted or substituted preferably as described for substituted aryl. - Halo(geno) is preferably iodo, bromo, chloro or fluoro, especially fluoro, chloro or bromo. 30
R
1 is preferably amino; halo, such as especially chloro; alkyl-amino, such as especially methylamino; mono- or di-(C 1
.
7 )alkyl-amino-lower alkyl, such as especially methylamino-methyl or dimethylamino-methyl; (Cl.
7 )alkoxy-carbonyl, such as especially methoxy-carbonyl; mono- or di
(C
1
.
7 )alkyl-amino-carbonyl, such as especially methylamino-carbonyl or dimethylamino-carbonyl; 35 (C 1
.
7 )alkyl-carbonyl-amino such as especially methylcarbonyl-amino; or (C 1
.
7 )alkoxy-carbonyl amino, such as especially methoxycarbonyl-amino.
WO 2007/031265 PCT/EP2006/008857 4
R
2 is preferably a cyclohexyl, phenyl or pyridyl, especially a phenyl, radical wherein said radical is substituted by one or more, especially 1 or 2, substituents independently selected from the group consisting of (C 1
.
7 )alkyl; halo; halo(C 1
.
7 )alkyl, such as especially trifluoromethyl; morpholinyl, such as especially morpholin-4-yl; morpholinyl-lower alkyl, such as especially morpholin-4-ylmethyl; and 5 (C 1
.
7 )alkyl-piperazinyl-(C 1
.
7 )alkyl, such as especially 4-methylpiperazin-1-ylmethyl. Preferably X is =C(R 7 )- and one of A and B is N while the other is -C(R 7 )-; most preferably X and A are both =CH- and B is N. 10 Preferably E, G and T are =C(R 7 )-; most preferably E, G and T are all =CH-.
R
7 and Ra are preferably H or halo. Y is preferably -0-. 15 Z is preferably N or C, most preferably C. Q is preferably (C 2 -4)alkenylene, or (C 4)alkylene wherein one or more, especially one, of the carbon atoms of (C 1 4)alkylene is replaced by a heteroatom independently selected from N, 0, S, 20 especially from 0. Q is especially selected from -O-CH 2 -[Z], -0-CH 2
-CH
2 -[Z], -CH=CH- and CH=CH-CH=, wherein "-[Z]" indicates where the bivalent radical is bound to Z in formula I if there are two possibilities; most preferably Q is -CH=CH-CH=. W is preferably not present. 25 In another aspect the VEGF receptor inhibitor is a compound of formula I , wherein
R
1 is halo; -(Co.
7
)-NR
4
R
5 ; or -C(=0)-R 6 ;
R
2 is a cyclohexyl, phenyl, pyridyl, 2H-indazolyl, 1,3-dihydro-2-benzofuranyl or pyrazole radical wherein said radical is substituted by one or more substituents independently selected from 30 the group consisting of lower alkyl; (C3e)cycloalkyl; (C 1 4)alkoxy; halo; halo-(C 1 4)alkyl; halo-(C 1 . 4 )alkoxy; SF 5 ; morpholinyl; morpholinyl-(C 1 4)alkyl; piperazinyl-(C,4)alkyl; (C 1 .4)alkyl piperazinyl-(C 1 4)alkyl and phenyl, wherein said phenyl is optionally substituted by (C 1 4)alkyl, halo, di-(C 1 4)alkyl-amino-(C 1 4)alkyl, (C 1 4)alkyl-piperazinyl-(C 4)alky or morpholinyl-(C 4)alkyl;
R
4 and R 5 are independently selected from the group consisting of H; (C 1 4)alkyl; (C,4)alkyl 35 carbonyl; and (C 4)alkoxy-carbonyl;
R
6 is (C 1 4)alkoxy, (C 1 4)alkyl-amino or di-(C 1 .4)alkyl-amino; X is =C(R 7 )- and one of A and B is N while the other is =C(R 7
)-;
WO 2007/031265 PCT/EP2006/008857 5 E, G and T are =C(R)-;
R
7 and R 8 are independently selected from the group consisting of H and halo; Y is -0-; Z is N and 0 is (C 2
.
3 )alkylene or (C 2
-
3 )alkenylene, wherein one of the carbon atoms of said (C 1 . 5 4)alkylene chain optionally may be replaced by oxygen; and the bond between 0 and Z characterized by a dotted line in formula I is a single bond; with the proviso that a is not unsubstituted unbranched (C 1 .4)alkylene; or Z is C and 0 is -CH=CH-CH=; and W is not present. 10 In another aspect of the present invention the VEGF receptor inhibitor is a compound of formula 1, wherein Z is C and Q is -CH=CH-CH=. 15 In another aspect of the present invention the VEGF receptor inhibitor is a compound of formula (I), wherein
R
1 is halo; -(Co.
7
)-NR
4
R
5 ; or -C(=O)-R 6 ;
R
2 is substituted (C3-B)cycloalkyl; substituted aryl; or substituted heterocyclyl;
R
4 and R 5 are independently selected from the group consisting of H; (C 1 .4)alkyl; (C 1 4)alkyl 20 carbonyl; and (C 1 .4)alkoxy-carbonyl;
R
6 is (C 1
.
4 )alkyl, (C 1 .4)alkoxy, (C 1 4)alkyl-amino, di-(C 1 .4)alkyl-amino-(C 1 4)alkyl-amino or di-(C 1 . 4 )alkyl-amino; A, B and X are independently selected from =C(R 7 )- or N; E, G and T are =C(R 8 )-; 25 R 7 and R 8 are independently selected from H and halo; Y is -0-, -S- or -CH 2 -, especially -0-; Z is N and Q is (C 1 4)alkylene or (C 2 4)alkenylene, wherein one or more, especially one, of the carbon atoms of said (C 1 4)alkylene or (C 2 4)alkenylene chain optionally may be replaced by a heteroatom independently selected from N, 0 and S, especially from 0, the N optionally 30 substituted by (C 1 .4)alkyl; and the bond between 0 and Z characterized by a dotted line in formula I is a single bond; with the proviso that 0 is not unsubstituted unbranched (C 1 4)alkylene; or Z is C and Q is as defined above wherein the bond between Q and Z characterized by a dotted line in formula I is a double bond; and W is (C 1
.
3 )alkylene or especially not present. 35 In another aspect of the present invention the VEGF inhibitor is a compound of formula (1), wherein WO 2007/031265 PCT/EP2006/008857 6 Z is N and Q is (C 2 4)alkenylene, or (C 1 4)alkylene wherein one or more, especially one, of the carbon atoms of (C 1 .4)alkylene is replaced by a heteroatom independently selected from N, 0 and S, especially from 0; and the bond between Q and Z characterized by a dotted line in formula I is a single bond; or 5 Z is C and Q is as defined above wherein the bond between 0 and Z characterized by a dotted line in formula I is a double bond. In a further aspect of the present invention the VEGF receptor inhibitor is a compound of formula (1), wherein 10 A is N and B is =CH or B is N and A is =CH, X is =CH, Y is 0, E, G and T are =CH, Z is C, 15 0 is -CH=CH-CH=, W is not present,
R
1 is -(CO.
7
)-NR
4
R
5 and R 4 and R 5 are as defined above,
R
2 is substituted aryl. 20 In another aspect of the present invention the VEGF receptor inhibitor is a compound of formula (11), wherein R 9 and Ria are each independently of the other hydrogen, unsubstituted or substituted alkyl or (C")cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula R 12 -Y-(C=Z)- wherein R 12 is unsubstituted, mono- or disubstituted amino or a heterocyclic radical, Y is either not present or (C 1
.
7 )alkyl and Z is oxygen or sulfur or imino, with the proviso that 25 R 9 and R 10 are not both hydrogen; or
R
9 and R 10 together with the nitrogen atom to which they are attached form a heterocyclic radical; RI, is a heterocyclic radical or an unsubstituted or substituted aromatic radical; K is C-C 7 -alkylene; M is -NH- or -0-; and 30 V is either not present or C-C 7 -alkylene, with the proviso that a heterocyclic radical R 11 is bonded via a ring carbon atom if V is not present. In another aspect of the present invention the VEGF receptor inhibitor is a compound of formula 11, wherein 35 R 9 and R 10 are each independently of the other hydrogen, (C 17 )alkyl, hydroxy-(C 1
.
7 )alkyl, or a radical of the formula R 12 -Y-(C=Z)- wherein R 12 is di-(C 17 )alkylamino, pyrrolidinyl, piperidyl, (C WO 2007/031265 PCT/EP2006/008857 7 7 )alkyl-piperazinyl, morpholinyl or pyridyl, Y is either not present or (C 1
.
7 )alkyl and Z is oxygen, with the proviso that R 9 and R 10 are not both hydrogen; or
R
9 and R 10 together with the nitrogen atom to which they are attached form a radical selected from the group consisting of pyrrolidinyl, piperidyl, (C 1
.
7 )alkyl-piperazinyl, di-(C 1
.
7 )alkyl-piperazinyl and 5 morpholinyl;
R
11 is phenyl, benzodioxolyl, pyridyl substituted by hydroxy or (C 1
.
7 )alkoxy, or phenyl substituted by one or more radicals selected independently of one another from the group consisting of (C 1 . 7 )alkyl, hydroxy, (C 1
.
7 )alkoxy, halogen and benzyloxy; K is -CH 2 -; 10 M is -NH-; and V is either not present, -CH 2 - or -CH(CH 3 )-, with the proviso that substituted pyridyl R 11 is bonded via a ring carbon atom if V is not present. In a further aspect of the present invention the VEGF receptor inhibitor is compound of formula 0 N -N
NH
2 F 0 N H F 15 F or a pharmaceutically acceptable salt thereof. In a further aspect of the present invention the VEGF receptor inhibitor is - 1-(4-chloroanilino)-4-(4-pyridylmethyl)-phthalazine or 20 - a compound of formula CH 3 NN N N 0\ / or a pharmaceutically acceptable salt thereof. Compositions provided by the present invention are hereinafter designated as "composition(s) of 25 (according to) the present invention". The VEGF receptor inhibitor in a composition of the present WO 2007/031265 PCT/EP2006/008857 8 invention includes a VEGF receptor inhibitor in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate. We now found that a combination of VEGF receptor inhibitor compounds of the present invention 5 when combined with a substance selected from the group consisting of unsaturated fatty acids, unsaturated fatty acid esters and unsaturated fatty acid alcohols to enhanced skin penetration. This was surprising, especially in view of the fact that a combination of DMSO, which is known to be one of the standard penetration enhancers, when applied together with a VEGF receptor inhibitor compound of the present invention does not work, i.e. no penetration enhancing effect has 10 been found. "Penetration enhancer" as used herein means a substance that enhances, i.e. improves the penetration of a VEGF receptor inhibitor, e.g. a compound of formula I or II, e.g. when administered topically (epicutanously), into skin or mucosa, e.g. into skin, such as the lower 15 epidermis and the dermis, compared with the penetration for a VEGF receptor inhibitor without that penetration enhancer. This enhanced penetration will lead to higher levels within the skin, in particular in the lower epidermis and the dermis. Higher penetration may also result in an increased permeation, e.g. increased permeation through the skin. Preferably the delivery of a VEGF receptor inhibitor to the systemic circulation is not or not significantly enhanced. 20 In another aspect of the present invention the penetration enhancer is a skin penetration enhancer selected from the group consisting of unsaturated fatty acids, unsaturated fatty acid esters and unsaturated fatty acid alcohols, e.g. oleyl alcohol. 25 In a further aspect the present invention provides a composition of the present invention in a form for topical administration, e.g. as a cream, gel, spray. A penetration enhancer preferably is present in an amount between 1 to 20 % w/w, more preferably between 1 to 10% w/w. 30 In another aspect the present invention provides a VEGF receptor inhibitor in a composition of the present invention is in the form of a salt. Such salts include preferably pharmaceutically acceptable salts, although pharmaceutically 35 unacceptable salts are included, e.g. for preparation / isolation / purification purposes. A salt of a compound of the present invention includes a metal salt or an acid addition salt. Metal salts include for example alkali or earth alkali salts; acid addition salts include salts of a compound WO 2007/031265 PCT/EP2006/008857 9 of formula I with an acid, e.g. hydrogen fumaric acid, fumaric acid, naphthalin-1,5-sulphonic acid, hydrochloric acid, deuterochloric acid; preferably hydrochloric acid. A VEGF receptor inhibitor in a composition of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A VEGF receptor inhibitor of 5 the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a corresponding compound in free form or in the form of a salt in non-solvated form; and vice versa. A VEGF receptor inhibitor in a composition of the present invention may exist in the form of pure 10 isomers or mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans isomers. A VEGF receptor inhibitor in a composition of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g. racemates. Any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S) configuration, preferably in the (R)- or (S)-configuration. 15 Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a VEGF 'receptor inhibitor in any isomeric form and in any isomeric mixture. The present invention also includes tautomers of a VEGF receptor inhibitor, e.g. a compound of 20 formula I, where tautomers can exist. VEGF receptor inhibitors, e.g. compounds of formula I, are prepared analogously to methods that, for other compounds, are in principle known in the art, and are especially prepared according to the methods described herein below under 'Examples'. 25 The starting materials used in the preparation of the VEGF receptor inhibitors, e.g. compounds of formula I are known, capable of being prepared according to known processes, or commercially obtainable. In particular, the anilines to be used as starting material in the preparation of the compounds of formula I can be prepared as described in WO 03/099771 or analogously thereto, 30 are commercially available or can be prepared according to known processes. The compositions of the present invention, e.g. including a compound of formula I, exhibit pharmacological activity and are therefore useful as pharmaceuticals. 35 In another aspect the present invention provides a composition for use as a pharmaceutical, e.g. a pharmaceutical for topical administration, e.g. in the form of a cream.
WO 2007/031265 PCT/EP2006/008857 10 A composition of the present invention shows therapeutic activity in dermatological diseases, e.g. proriasis, atopic dermatitis and acne. In a further aspect the present invention provides a composition of the present invention for the 5 manufacture of a medicament for the treatment of a dermatological disease, e.g. selected from the group consisting of psoriasis, atopic dermatitis and acne. For pharmaceutical use a composition of the present invention includes one or more, preferably one, VEGF receptor inhibitors, e.g. a combination of two or more VEGF receptor inhibitors. 10 In another aspect the present invention provides the use of a composition of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a dermatological disease, e.g. selected from the group consisting of psoriasis, atopic dermatitis and acne. 15 In a further aspect the present invention provides a method of treatment of a dermatological disease selected from the group consisting of psoriasis, atopic dermatitis and acne, which treatment comprises administering to a subject in need of such treatment an effective amount of a composition of the present invention. 20 Treatment includes treatment and prophylaxis. For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmacokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of 25 the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.01 g to about 1.0 g, of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day. 30 A composition of the present invention may be administered topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops or sprays. A composition of the present invention may be used for pharmaceutical treatment according to the 35 present invention alone or in combination with one or more other pharmaceutically active agents. Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instruction for co-administration; and free C \NRPonblDCC\RBR\30tx0%.1 DOC-i )20II 11 combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given. In another aspect the present invention provides a pharmaceutical composition comprising a 5 compound of the present invention in association with at least one pharmaceutical excipient, e.g. appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers. 10 In another aspect the present invention provides a pharmaceutical composition of the present invention, further comprising another pharmaceutically active agent. Such compositions may be manufactured according, e.g. analogously to a method as conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit dosage forms may 15 contain, for example, from about 0.5 mg to about 1000 mg, such as 1 mg to about 500 mg. In a further aspect the present invention provides a kit of parts for use in the treatment of a dermatological disease selected from the group consisting of psoriasis, atopic dermatitis and acne a) a VEGF receptor inhibitor, of formula 1, and 20 b) a penetration enhancer, selected from the group consisting of unsaturated fatty acids, unsaturated fatty acid esters and unsaturated fatty acid alcohols. The following Examples serve to illustrate the invention without limiting the scope thereof 25 Temperatures are given in degrees Celsius (0). Unless otherwise indicated, the reactions take place at room temperature under N 2 -atmosphere. The R 1 values which indicate the ratio of the distance moved by each substance to the distance moved by the eluent front are determined on silica gel thin-layer plates (Merck, Darmstadt, 30 Germany) by thin-layer chromatography using the respective named solvent systems. Abbreviations.: Anal. elemental analysis (for indicated atoms, difference between calculated and 35 measured value s 0.4 %) aq. aqueous brine saturated solution of NaCl in H 2 0 BuOH butanol conc. concentrated WO 2007/031265 PCT/EP2006/008857 12 DEPC diethyl-cyanophosphonate DIPE diisopropyl-ether DMAP dimethylaminopyridine DMF dimethyl formamide 5 DMSO dimethyl sulfoxide ether diethylether Et 3 N triethylamine EtOAc ethyl acetate EtOH ethanol 10 eq. equivalent Ex. Example h hour(s) HATU O-(7-azabenzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium-hexafluorophosphate HPLC high pressure liquid chromatography 15 1 litre(s) Me methyl MeOH methanol min minute(s) m.p. melting point 20 MPLC medium pressure liquid chromatography - Combi Flash system: normal phase SiO 2 - Gilson system: reversed phase Nucleosil C1 8 (H 2 0/CH 3 CN + TFA), generally product obtained as free base after neutralization with NaHCO 3 MS mass spectrum 25 NMM N-methyl-morpholine NMP N-methyl-pyrrolidone prep-HPLC preparative high pressure liquid chromatography; Waters system ; column: reversed phase AtlantisTM (100 X 19 mm), dC18 OBD (H 2 0/CH 3 CN + 0.1% TFA), 5 pM, generally product obtained as a TFA salt after lyophilization. 30 propylphosphonic anhydride N-propylphosphonic acid anhydride, cyclic trimer [68957-94-8]; 50 % in DMF Rf ratio of fronts (TLC) rt room temperature sat. saturated 35 THF tetrahydrofuran (distilled from Na/benzophenone) TFA trifluoroacetic acid TLC thin layer chromatography WO 2007/031265 PCT/EP2006/008857 13 tRet retention time (HPLC) triphosgene bis(trichloromethyl) carbonate HPLC Conditions: 5 AtRet: retention time [min] for System A: Linear gradient 20-100% CH 3 CN (0.1% TFA) and H 2 0 (0.1% TFA) in 13 min + 5 min 100% CH 3 CN (0.1% TFA); detection at 215 nm, flow rate 1 ml/min at 25 or 30 *C. Column: Nucleosil 120-3 C18 (125 x 3.0 mm). BtRet: retention time [min] for System B: Linear gradient 5-40% CH 3 CN (0.1% TFA) and H 2 0 (0.1% TFA) in 9 min + 7 min 40% CH 3 CN (0.1% TFA); detection at 215 nm, flow rate 1 ml/min at 25 10 or 30 *C. Column: Nucleosil 120-3 C1 8 (125 x 3.0 mm). ctRe: retention time [min] for System C Linear gradient 15-100% CH 3 CN (0.1% TFA) and H 2 0 (0.1% TFA) in 2.25 min + 1.25 min 100% CH 3 CN (0.1% TFA); detection at 215 nm, flow rate 2 ml/min at 25 or 30 C. Column: CC (50 x 4.6 mm) Uptisphere UP30DB-5QS. DtRet: retention time [min] for System D- Linear gradient 20-100% CH 3 CN (0.1% TFA) and H 2 0 15 (0.1% TFA) in 5 min + 1 min 100% CH 3 CN (0.1% TFA); detection at 215 nm, flow rate 1 ml/min at 25 or 30 C. Column: CC (250 x 4.6 mm) Nucleosil 100-5 C18. EtRet: retention time [min] for System E Linear gradient 20-100% CH 3 CN (0.1% TFA) and H 2 0 (0.1% TFA) in 14 min + 5 min 100% CH 3 CN (0.1% TFA); detection at 215 nm, flow rate 1 ml/min at 25 or 30 *C. Column: CC 70/4 (70 x 4.0 mm) Nucleosil 100-3 C18. 20 FtRef: retention time [min] for System F: Linear gradient 5-100% CH 3 CN and H 2 0 (0.1 % TFA) in 4 min + 0.5 min 100% CH 3 CN; PDA MaxPlot detection (210.0 nm to 400.0 nm), flow rate 3 ml/min at 35 C. Column: SunfireTM (4.6 x 20 mm) C18, 3.5 pm. GtRet: retention time [min] for System G: Linear gradient 5-100% CH 3 CN (0.07% formic acid) and
H
2 0 (0.1% formic acid) in 4 min + 0.5 min 100% CH 3 CN (0.07% formic acid); PDA MaxPlot 25 detection (210.0 nm to 400.0 nm), flow rate 1.8 m/min at 40 0 C. Column: X-TerraTM (4.6 x 50 mm) MSC18, 5 pm.
WO 2007/031265 PCT/EP2006/008857 14 Example 1: rac-5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2.3-dihydro-indole-1 carboxylic acid (3-trifluoromethyl-phenvl)-amide 0.68 mMol rac-5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro-indole (Step 1.2) are dissolved in 5 ml THF. Then 106 pl (0.77 mMol) 3-trifluoromethyl-phenylisocyanat 5 are added and the solution is stirred for 1 h at rt. Concentration and chromatography (Combi Flash; EtOAc/hexane 1:9 -+ 1:1) gives the title compound: MS: [M+1J]= 482/484; HPLC: AtRet = 16.4; Anal.: C,H,N,CI,F. The starting material is prepared as follows: 10 Step 1.1: 5-(2-Amino-6-chloro-pyrimidin-4-vloxy)-4-fluoro-2-methvl-1H-indole 1.00 g (6.05 mMol) 2-amino-4,6-dichloro-pyrimidine and 993 mg (6.05 mMol) 4-fluoro-5-hydroxy-2 methylindole [preparation see: WO 00/47212 Ex. 237] are suspended in 25 ml acetone. Then 12 ml 1 N NaOH in H 2 0 are added and the mixture is stirred at an oilbath temperature of 70 0C for 5 h. Then additional 210 mg 2-amino-4,6-dichloro-pyrimidine are added portionwise 15 and stirring continued for another 4.5 h. The reaction mixture is partially concentrated and the crystallized title compound filtered off and washed with H 2 0: m.p.: 255-258 cC; MS: [M+1]*= 293/295; HPLC: AtRet = 13.7. Step 1.2: rac-5-(2-Amino-6-chloro-pyrimidin-4-vloxV)-4-fluoro-2-methyl-2.3-dihydro-1H-indole 20 A solution of 200 mg (0.68 mMol) of 5-(2-amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-1H indole in 4 ml acetic acid is cooled to 10-15 0C. Then 214 mg (3.4 mMol) NaBH 3 CN are added. After 3 h stirring at rt, 8 g of ice are added, then the mixture is made basic by addition of 1 N NaOH and extracted three times with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated at rt in vacuo: HPLC: At Ret = 9.9. 25 Example 2: rac-5-(2-Amino-pyrimidin-4-vloxy)-4-fluoro-2-methyl-2.3-dihvdro-indole-1 -carboxylic acid (3-trifluoromethyl-phenvl)-amide A solution of 230 mg (0.48 mMol) rac-5-(2-amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3 dihydro-indole-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide and 75 il (0.54 mMol) Et 3 N 30 in 12 ml THF is hydrogenated in the presence of 63 mg Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated and the residue dissolved in EtOAc and H 2 0. The aqueous layer is extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Crystallization from EtOAc/DIPE gives the title compound: MS: [M+1]I= 448; HPLC: AtRet = 12.7. 35 Example 3: 5-(6-Chloro-pyrimidin-4-vloxy)-indole-1 -carboxylic acid (3-trifluoromethyl-phenyl) amide WO 2007/031265 PCT/EP2006/008857 15 A solution of 492 mg (2.00 mMol) of 5-(6-chloro-pyrimidin-4-yloxy)-1H-indole (WO 03/099771; Stage 163.1), 344 mg (2.12 mMol) of 1,1'-carbonyl-diimidazol and 6 mg DMAP in 7 ml
CH
3 CN is stirred at 80 *C for 8 h. After cooling to rt, 356 pl (2.86 mMol) 3-trifluoromethyl aniline are added to the suspension, which then is stirred again for 9 h at 80 *C. The reaction 5 mixture is filtered and the filtrate diluted with EtOAc and H 2 0. The aqueous layer is extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Reversed phase MPLC (Gilson system) gives the title compound: MS: [M+1]* = 433/435; TLC(EtOAc/CH 2
CI
2 3:97): Rf = 0.15; HPLC: At, = 16.8. 10 Example 4: 5-(6-Amino-pyrimidin-4-yloxy)-indole-1 -carboxylic acid (3-trifluoromethyl-phenyl) amide To a solution of 150 mg (0.35 mMol) 5-(6-chloro-pyrimidin-4-yloxy)-indole-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide in 2 ml DMF, 45 mg (0.69 mMol) NaN 3 are added at rt. After 2 h at 65 *C, the solution containing 5-(6-azido-pyrimidin-4-yloxy)-indole-1 -carboxylic acid (3 15 trifluoromethyl-phenyl)-amide is cooled to rt. Then 12 mg Pd/C (10 %; Engelhard 4505) are added and the mixture is hydrogenated for 1 h. The catalyst is filtered off and the filtrate concentrated in vacuo. Reversed phase MPLC (Gilson system) gives the title compound: MS: [M+1]'= 414; HPLC: ARet = 12.6. 20 Example 5: 7-(6-Amino-pyrimidin-4-vloxy)-2,3-dihvdro-benzof[,41oxazine-4-carboxylic acid (4 methyl-3-trifluoromethyl-phenvl)-amide 104 mg (0.35 mMol) triphosgene are disolved in 13 ml ice cooled CH 2 Cl 2 . Then a solution of 183 mg (1.05 mMol) 5-amino-2-methylbenzotrifluoride and 209 pl (1.5 mMol) Et 3 N in 6 ml CH 2 Cl2 is added during 8 min. After 3 minutes, the mixture is warmed up to rt by a H 2 0 bath and 25 then a solution of 244 mg (1.00 mMol) 6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy) pyrimidin-4-ylamine (Step 5.6) and 139 pl (1.0 mMol) Et 3 N in 6 ml CH 2 Cl 2 is added during 10 min. After 2.5 h at rt, the mixture is diluted with sat. Na 2
CO
3
/H
2 0 1:1 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with
H
2 0 and brine, dried (Na 2
SO
4 ) and concentrated partially. Addition of ether and hexane gives 30 the crystalline title compound: MS: [M+1]*= 446; TLC(EtOAc): Rf = 0.30; HPLC: At Re = 12.3. The starting material is prepared as follows: Step, 5.1: 2-(2.4-Dimethoxy-phenvlamino)-ethano 30.6 g (0.20 Mol) 2,4-dimethoxy-aniline are dissolved in 200 ml EtOAc. Then 14.8 ml (95 %; 0.20 35 Mol) of 2-bromethanol and 33.6 g (0.40 Mol) NaHCO 3 are added and the suspension is heated to 77 *C for 20 h. The mixture is cooled to rt and filtered. Concentration of the filtrate WO 2007/031265 PCT/EP2006/008857 16 and column chromatography (SiO 2 ; hexane/EtOAc 3:1 -) 2:1 -+ 1:1) gives the title compound as an oil: MS: [M+1]*= 198; TLC(EtOAc): R, = 0.50; HPLC: BtRet = 9.2. Step 5.2: (2-Bromo-ethyl)-(2,4-dihydroxy-phenyl)-carbamic acid benzyl ester 5 22 g (0.11 Mol) 2-(2,4-dimethoxy-phenylamino)-ethano and 125 ml HBr (62 % in H 2 0) are heated to 140 0C for 15 h. The resulting dark solution is concentrated in vacuo. The residue is diluted with 60 ml H 2 0 and 120 ml EtOAc and cooled in an ice bath. Then 30 ml (95 %; 0.20 Mol) benzyl chloroformate are added. Under vigorous stirring, 90 ml Na 2
CO
3 2 M are added dropwise during 20 min. After 90 min stirring at rt, the reaction mixture is filtered, the 10 aqueous phase of the filtrate separated off and extracted twice with 30 ml EtOAc. The organic layers are washed with 30 ml brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; hexane/EtOAc 4:1 -+ 7:3 -> 3:2) gives the title compound as an oil: MS: [M+1]*= 366/368; TLC(EtOAc/hexane 1:1): R, = 0.34; HPLC: At Ret = 12.6. 15 Step 5.3: 7-Hydroxy-2.3-dihvdro-benzof1,4]oxazine-4-carboxvlic acid benzyl ester To a solution of 32 g (87.4 mMol) (2-bromo-ethyl)-(2,4-dihydroxy-phenyl)-carbamic acid benzyl ester in 100 ml DMF, 16 g (116 mMol) K 2
CO
3 are added. After 1 h stirring at rt, the reaction mixture is filtered and the filtrate concentrated in vacuo. The resulting brown oil is diluted with 120 ml EtOAc and 50 ml citric acid (5 % in H 2 0). The aqueous phase is separated off and 20 extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated, giving the oily title compound: MS: [M+1 ]* = 286; TLC(EtOAc/hexane 1:1): Rf = 0.61; HPLC: AtRet = 13.0. Step 5.4: 7-(6-Chloro-pyrimidin-4-vloxy)-2,3-dihvdro-benzo[1.4]oxazine-4-carboxylic acid benzvl 25 ester To a solution of 9.73 g (95 %; 32.5 mMol) 7-hydroxy-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid benzyl ester in 96 ml of acetone, 4.84 g (32.5 mMol) 4,6-dichloropyrimidine are added. Then a solution of 1.3 g (32.5 mMol) NaOH in 48 ml of H 2 0 is added and the mixture stirred for 2 h at rt. Addition of some seeding crystals leads to the crystallization of the title 30 compound, which is filtered off and washed with acetone/H 2 0 1:1: m.p.: 110 *C; MS: [M+1]*= 398/400; HPLC: AtRe = 16.4. More product can be isolated from the filtrate by extraction (EtOAc; NaHCO 3 , H 2 0 and brine) and column chromatography (SiO 2 ; hexane/EtOAc 9:1 - 4:1 -+ 3:1). 35 Step 5.5: 7-(6-Azido-pvrimidin-4-vloxy)-2.3-dihvdro-benzol,4]oxazine-4-carboxylic acid benzvl ester WO 2007/031265 PCT/EP2006/008857 17 To a solution of 8.0 g (20.1 mMol) 7-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4 carboxylic acid benzyl ester in 35 ml DMF, 2.61 g (40.2 mMol) NaN 3 are added. After heating at 70 *C for 90 min, the resulting mixture is diluted with EtOAc and H 2 0, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and 5 brine, dried (Na 2
SO
4 ) and concentrated, giving the title compound: MS: [M+1 ]+ = 405; HPLC: AtRe = 16.6. Step 5.6: 6-(3.4-Dihvdro-2H-benzo[l,4]oxazin-7-vloxy)-pyrimidin-4-vlamine A solution of 20.1 mMol 7-(6-azido-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic 10 acid benzyl ester in 500 ml THF is hydrogenated in the presence of 3.5 g Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated and crystallized from DIPE, giving the title compound: m.p.: 140-141 "C; MS: [M+1]*= 245; TLC(EtOAc): Rf = 0.11. Example 6: 7-(6-Amino-pyrimidin-4-vloxy)-2.3-dihydro-benzo[1.4loxazine-4-carboxylic acid (4 15 fluoro-3-trifluoromethyl-phenyl)-amide Prepared analogously to Ex. 5: MS: [M+1]*= 450; TLC(EtOAc): Rf = 0.23; HPLC: At Ret = 11.9. Example 7: 7-(6-Amino-pyrimidin-4-vloxy)-2.3-dihvdro-benzo[l,4]oxazine-4-carboxylic acid (3 trifluoromethyl-phenvl)-amide 20 A solution of 120 pl (0.87 mMol) 3-trifluoromethyl-phenyl-isocyanate in 9 ml ether is added dropwise to 0.20 g (0.82 mMol) 6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-4 ylamine in 4.5 ml THF. After 45 min at rt, 10 ml hexane are added. Then the crystallized title compound is filtered off and washed with hexane: MS: [M+1]*= 432; TLC(EtOAc): Rf = 0.32; HPLC: tRet = 11.9; Anal.: C,H,N,F. 25 Example 8: 7-(6-Methylamino-pyrimidin-4-vloxy)-2.3-dihvdro-benzo[1,4loxazine-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenvl)-amide 73 mg (0.25 mMol) triphosgene are disolved in 9 ml ice cooled CH 2
CI
2 . Then a solution of 134 mg (97 %; 0.74 mMol) 5-amino-2-methylbenzotrifluoride and 146 p (1.05 mMol) Et 3 N in 4 ml 30 CH 2 Cl 2 is added during 5 min. After 3 minutes, the mixture is warmed up to rt by a H 2 0 bath and then a solution of 180 mg (0.70 mMol) [6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy) pyrimidin-4-yl]-methyl-amine (Step 8.2) and 98 pl (0.70 mMol) Et 3 N in 4 ml CH 2
CI
2 is added during 5 min. After 2.5 h at rt, the mixture is diluted with sat. Na 2
CO
3
/H
2 0 1:1 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are 35 washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Crystallization from THF and hexane gives the title compound: m.p.: 180-182 0C; MS: [M+1 ]* = 460; TLC(EtOAc): Rf = 0.38; HPLC: BtRe, = 12.7.
WO 2007/031265 PCT/EP2006/008857 18 The starting material is prepared as follows: Step 8.1: 7-(6-Methylamino-pyrimidin-4-vloxy)-2,3-dihvdro-benzo[1,4loxazine-4-carboxylic acid benzyl ester 5 To a suspension of 1.39 g (3.49 mMol) 7-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro benzo[1,4]oxazine-4-carboxylic acid benzyl ester (Step 5.4) in 8 ml THF, 8.7 ml (2 M in THF; 17.5 mMol) methylamine are added. After stirring in a sealed vessel for 16 h at rt, the resulting mixture is dissolved with EtOAc and MeOH. Then 6 g of SiO 2 are added and the mixture is concentrated in vacuo. The resulting powder is put on top of a SiO 2 column 10 (EtOAc/hexane 1:3) and the title compound eluted with EtOAc/hexane 1:3 -- 4 1:1 -> 2:1: MS: [M+1]*= 393; TLC(EtOAc/hexane 1:1): Rf = 0.08; HPLC: AtRet= 12.1. Step 8.2: [6-(3,4-Dihydro-2H-benzo[1,4]oxazin-7-vloxy)-pyrimidin-4-Vl]-methVl-amine A solution of 0.79 g (2.0 mMol) 7-(6-methylamino-pyrimidin-4-yloxy)-2,3-dihydro 15 benzo[1,4]oxazine-4-carboxylic acid benzyl ester in 50 ml THF is hydrogenated in the presence of 0.35 g Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated partially and the title compound crystallized by addition of hexane: m.p.: 153 *C; MS: [M+1]*= 259; TLC(EtOAc): R, = 0.16; HPLC: BtRet = 10.6. 20 Example 9: 7-(6-Methylamino-pyrimidin-4-vloxy)-2,3-dihvdro-benzorl.4oxazine-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide Prepared analogously to Ex. 7: m.p.: 180 "C; MS: [M+1]*= 446; TLC(EtOAc): Rf = 0.47; HPLC: At Ret = 12.3; Anal.: C,H,N,F. 25 Example 10: 7-(2-Amino-pyrimidin-4-vloxy)-2.3-dihvdro-benzo1.4]oxazine-4-carboxylic acid (3 trifluoromethyl-phenvl)-amide A solution of 0.183 g (0.75 mMol) 4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine (Step 10.2) in 3 ml of acetonitrile is treated at rt with 0.114 ml (0.825 mMol) 1-isocyanato-3 trifluoromethyl-benzene and stirred for 2 h at rt. The solvent is evaporated and the residue 30 chromatographed on a 40 g silica gel column on a Combi-Flash Companion T M (Isco Inc.) apparatus using EtOAc as solvent. The title compound is obtained as a colorless foam: MS: [M+1 ]* = 432; TLC(EtOAc): Rf = 0.31; HPLC: ctRet = 1.88 min. The starting material is prepared as follows: 35 Step 10.1: 7-(2-amino-6-chloro-pyrimidin-4-vloxy)-2.3-dihvdro-benzo[1.4loxazine-4-carboxylic acid benzyl ester WO 2007/031265 PCT/EP2006/008857 19 To a solution of 5.8 g (0.0203 Mol) crude 7-hydroxy-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid benzyl ester (Step 5.3) in 30 ml of DMF are added 2.0 g anhydrous potassium carbonate and 3.3 g (0.0201 Mol) 2-amino-4,6-dichloropyrimidine and the resulting mixture is heated to 80 0 C for 16 h. After cooling to rt the mixture is filtered and the DMF evaporated to 5 leave a dark brown oil. This material is purified by flash-chromatography on a 240 g silica gel column using CH 2
CI
2 /MeOH 100:0.5 -4 100:2.5 as eluent. Pure fractions are evaporated to leave a yellow oil. On addition of 15 ml of EtOAc the product crystallizes. It is filtered off, washed with EtOAc/hexane 1:1 and dried. The title compound is obtained as colorless crystals: m.p. 161-163 0C; MS: [M+1]*= 412.9; TLC (CH 2 Cl 2 /MeOH/NH 3 aa 350:50:1): Rf = 10 0.76; HPLC: ctne = 2.57 min. Step 10.2: 4-(3,4-dihydro-2H-benzo[l,4]oxazin-7-vloxy)-pyrimidin-2-Vlamine 2.0 g (4.8 mMol) 7-(2-amino-6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4 carboxylic acid benzyl ester are dissolved in 100 ml of a 1:1 mixture of THF and methanol 15 and hydrogenated at rt in the presence of 0.5 g Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated and partitioned between 40 ml conc. sodium bicarbonate and 50 ml of EtOAc. The organic layer is washed with brine, dried with sodium sulfate and evaporated. The crude title compound is obtained as an amorphous material: MS: [M+1]*= 245; TLC(CH 2 Cl 2 /MeOH/NH 3 aq 350:50:1): Rf = 0.47; HPLC: CtRet = 0.86 min. 20 Example 11: 7-(2-Amino-pyrimidin-4-vloxy)-2,3-dihvdro-benzo[1.4]oxazine-4-carboxylic acid (4 morpholin-4-vlmethyl-3-trifluoromethyl-rphenvl)-amide A solution of 0.86 ml (7.13 mMol) trichloromethyl chloroformate in 4 ml of dry THF is treated at 40 0C with a solution of 0.51 g (2.09 mMol) 4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy) 25 pyrimidin-2-ylamine. The mixture is stirred under ref lux for 2 h, cooled to rt and evaporated to leave a tan foam. This is added to a solution of 4-morpholin-4-ylmethyl-3-trifluoromethyl phenylamine (0.362 g, 1.4 mMol) in 4 ml of ethanol. The mixture is heated to 80 *C and stirred at that temperature for 3 h. After cooling to rt the solvent is evaporated and the residue partitioned between CH 2 Cl 2 and sat. sodium bicarbonate solution. The organic phase 30 is dried with sodium sulfate and evaporated. The residue is purified on a 40 g silica gel column on a Combi-Flash CompanionTM (Isco Inc.) apparatus using EtOAc for 10 min, then a gradient of 1 to 30 % acetone in EtOAc. The title compound is obtained as a slightly reddish foam: MS: [M+1 ]* = 531; TLC (EtOAc): R = 0.10; HPLC: ctRet = 1.32 min. 35 Example 12: The following compounds can be obtained analogously to Ex. 10 or 11.
WO 2007/031265 PCT/EP2006/008857 20 rkr0 O1; O O 'Y0 S R1 N N / NN N / N
NH
2 H NH2 O N H R2 RI TLC HPLC MS O Rf toe, m.p. [*C] [M+1]* HN R2 [min] a) F F 0.231 12.7 500 F b) c.3 2.03c 127-130 465.8 HN") F F c) F F 2.13 146-149 499.9 HN F F d) HNXI1.92 119-124 449.9 H F e) c2.01F 191-195 465.9 HN F f) 1.977 133-136 445.9 HN'or F ' TLC(EtOAc/hexane 2:1); 2) TLC(-tOAc) R1 Most respective anilines are either commercially available or
H
2 N N described in WO 03/099771 or can be prepared analogously to the R2 therein exemplified derivatives. 5 Example 13: 6-(2-Amino-6-chloro-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-phenvl)-amide To an ice cooled solution of 3.5 g (11 mMol) 6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1 10 carboxylic acid in 60 ml DMF, 1.8 ml (16 mMol) NMM and 3.1 ml (20 mMol) DEPC are added, followed by 1.5 ml (12 mMol) of 3-amino-benzotrifluoride. After 2 h stirring at 0 *C and 16 h at rt, the solution is concentrated in vacuo. The residue is re-dissolved in H 2 0 and WO 2007/031265 PCT/EP2006/008857 21 EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed twice with H 2 0 and brine, dried (Na 2
SO
4 ) and after addition of SiO 2 concentrated. The resulting powder is put on top of a SiO 2 column (EtOAc/hexane 1:9) and eluted with EtOAc/hexane 1:9 -4 1:1. Partial concentration of the product containing fractions 5 leads to crystallization. Filtration and washing with hexane gives the title compound: m.p.: 234-236 0C; MS: [M+1]*= 459; TLC(EtOAc/hexane 1:2): R, = 0.24; HPLC: At = 16.2. The starting material is prepared as follows: Step 13.1: 6-(2-Amino-6-chloro-pyrimidin-4-vloxy)-naphthalene-1-carboxylic acid 10 A suspension of 6.56 g (40 mMol) 2-amino-4,6-dichloropyrimidine and 7.52 g (40 mMol) 6-hydroxy 1 -naphthoic acid in 160 ml acetone and 80 ml 1 N NaOH is heated to 62 0C for 36 h. The mixture is cooled to rt, partially concentrated in vacuo and the residue poured into 1.6 I ice
H
2 0. Under vigorous stirring, 20 ml 2 N HCI are added dropwise (pH = 4). After stirring the suspension for 30 min, the title compound is filtered off and washed with H 2 0: MS: [M+1]*= 15 316/318; HPLC: AtR = 12.8. Example 14: 6-(2-Amino-pyrimidin-4-vloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)-amide A solution of 660 mg (1.44 mMol) 6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic 20 acid (3-trifluoromethyl-phenyl)-amide in 70 ml THF and 0.22 ml (1.58 mMol) Et 3 N is hydrogenated in the presence of 0.4 g Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated and the residue diluted with EtOAc and H 2 0. The aqueous layer is extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 1:1 -> EtOAc) 25 gives the title compound: m.p.: 218 0C; MS: [M+1]*= 425; TLC(EtOAc/hexane 1:1): R, = 0.07. Example 15: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (4-methyl-3 trifluoromethyl-phenyl)-amide To an ice cooled solution of 140 mg (0.50 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1 30 carboxylic acid in 3 ml DMF, 78 pl (97 %; 0.53 mMol) 4-methyl-3-trifluoromethyl-aniline, 74 p1 (0.67 mMol) NMM and 124 gI (0.83 mMol) DEPC are added. After overnight stirring, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 4:1 -4 1:9) and crystallization 35 from hexane gives the title compound: MS: [M+1 ]* = 439; TLC(EtOAc): Rt = 0.49; HPLC: AtRet = 12.7.
WO 2007/031265 PCT/EP2006/008857 22 The starting material is prepared as follows: Step 15.1: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid A solution of 230 mg (0.73 mMol) 6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (Step 13.1) in 41 ml THF and 1 ml Et 3 N is hydrogenated in the presence of 0.17 g Pd/C 5 (10 %; Engelhard 4505). The catalyst is filtered off and the filtrate concentrated. The residue is dissolved in EtOAc and H 2 0 and the aqueous layer extracted twice with EtOAc. Acidification of the aqueous phase with 2 N HCI (-> pH 3-4) leads to the crystallization of the title compound, which is filtered off and washed with H 2 0: MS: [M+ 1]= 282; HPLC: BtRet = 13.6. 10 Example 16: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxVlic acid (2-trifluoromethyl pyridin-4-yl)-amide 0.24 mMol 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid, 43 mg (0.26 mMol) 4 amino-2-(trifluoromethyl)pyridine [J. Med. Chem. 36 (1993), 733-746], 20 mg (0.16 mMol) 15 DMAP and 0.8 ml (5.7 mMol) Et 3 N are dissolved in 4 ml DMF. Then 0.6 ml (1 mMol) propylphosphonic anhydride are added and the mixture is stirred for 3 days at rt. The mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Reversed phase chromatography gives the title compound: MS: [M+1]*= 426; HPLC: AtRe, = 20 11.9. Example 17: The following compounds can be obtained analogously to Ex. 15. ( rO (ryo R1 N N - N N
NH
2 0 OH NH 2 0 N R2 H 25 R1 TLC HPLC MS Rf AtRet m.p. [*C] [M+1I] Anal. HN R2 [min] a) F F 0.191) 12.4 425 HNXI b) 0.30 13.1 228-229 413 C,H,N WO 2007/031265 PCT/EP2006/008857 23 c) F 0 12.6 205-206 443 C,H,N F d) 0.29) 13.5 463/465 HN I'% r e) 12.3 493 HN /F F 1 TLC(EtOAc/hexane 2:1) Example 18: 6-(2-Acetylamino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenvl)-amide 5 A solution of 170 mg (0.40 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-phenyl)-amide (Ex. 14) in 3 ml pyridine is diluted with 2 ml CH 2
CI
2 . Then 0.20 ml of an acetylchloride solution (2.2 M in CH 2
C
2 ; 0.44 mMol) are added dropwise, followed by another 0.10 ml after 40 min. After totally 75 min, the reaction mixture is diluted with EtOAc and H 2 0. The aqueous layer is separated off and extracted twice with EtOAc. The 10 organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 1:1 -- > EtOAc), partial concentration and crystallization by addition of DIPE gives the title compound: m.p.: 216-217 0C; MS: [M+1]*= 467; TLC(EtOAc): Rf = 0.36; HPLC: At Ret = 13.1; Anal.: C,H,N,F. 15 Example 19: 6-(2-Methoxvcarbonylamino-pyrimidin-4-vloxy)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenvl)-amide A solution of 200 mg (0.47 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide (Ex. 14) in 5 ml pyridine is diluted with 3 ml CH 2 Cl 2 . Then 7.1 ml of a methyl chloroformate solution (2.8 M in CH 2 Cl 2 ; 20 mMol) are added portionwise 20 during 7 h. The reaction mixture is diluted with EtOAc and H 2 0. The aqueous layer is separeted off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Stirring in DIPE gives the title compound: m.p.: 199 200 0C; MS: [M+1]*= 483; HPLC: ^tRt = 13.6; Anal.: C,H,N,F. 25 Example 20: 7-(2-Acetylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide Prepared at 0 0C as described in Ex. 18 from 161 mg (0.36 mMol) 7-(2-amino-pyrimidin-4-yloxy) 2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide (Ex. 12f): MS: [M+1]*= 488; TLC(EtOAc): Rf = 0.47; HPLC: ^tRet = 12.9; Anal.: C,H,N,F. 30 WO 2007/031265 PCT/EP2006/008857 24 Example 21: 7-(2-Methoxvcarbonylamino-pyrimidin-4-vloxy)-2.3-dihvdro-benzo[1l,4oxazine-4 carboxylic acid (4-methyl-3-trifluoromethyl-phenvl)-amide Prepared as described in Ex. 19 from 150 mg (0.34 mMol) 7-(2-amino-pyrimidin-4-yloxy)-2,3 dihydro-benzo[1,4]oxazine-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide (Ex. 5 12f): MS: [M+1]*= 504; TLC(EtOAc): R, = 0.52; HPLC: AtRt = 13.3; Anal.: C,H,N,F. Example 22: 7-(2-Amino-pVrimidin-4-vloxy)-2,3-dihvdro-benzof1,4]oxazine-4-carboxylic acid [4-(4 methyl-piperazin-1-vi methyl)-3-trifluoromethyl-phenvl]-amide A solution of 0.174 g (0.71 mMol) 4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine 10 (Step 10.2) and 0.291 g (0.68 mMol) [4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl phenyl]-carbamic acid phenyl ester hydrochloride in 0.75 ml of DMSO is warmed to 60 *C. After the addition of 0.133 ml (0.77 mMol) of N,N-diisopropyl-ethylamine the mixture is stirred at 60 *C for 1.5 h. A solution of 0.055 g KOH in 0.1 ml of H 2 0 is added at 500C and the mixture stirred rapidly for about 10 min. After cooling to rt the mixture is partitioned between 15 EtOAc and H 2 0 and the organic layer washed with brine. 2 g of silica gel are added and the solvent evaporated. The resulting powder is applied to a 40 g silica gel column on a Combi Flash CompanionTM (Isco Inc.) apparatus and eluted with EtOAc (A) and MeOH/NH3a 10:3 (B) with a gradient of 0% B -+ 10% B in 30 min then 10% B for 20 min. The title compound is obtained as a yellowish foam: MS: [M+1]*= 543.9; TLC (CH2Cl2/MeOH/NH3ag 350:50:1): Rf = 20 0.36; HPLC: ctRet 1.30 min. The starting material is prepared as follows: Step 22.1: [4-(4-Methyl-piperazin-1 -vlmethyl)-3-trifluoromethyl-phenyll-carbamic acid Phenyl ester hydrochloride 25 As described in Synth. Commun. 30 (2000), 1937 the title compound can be prepared by dropwise addition of a solution of [4-(4-methyl-piperazin-1 -ylmethyl)-3-trifluoromethyl]-aniline (1.0 eq.) in THF to a solution of phenyl chloroformate (1.1 eq.) in THF at -25 0C and warming the mixture up to rt. 30 Example 23: 6-(2-Amino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (4-morpholin-4-vl-3 trifluoromethyl-phenyl)-amide To a solution of 184 mg (0.65 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (Step 15.1) in 5 ml NMP, 214 J (1.95 mMol) NMM and 247 mg (0.65 mMol) HATU are added. After 15 min stirring, 242 mg (0.98 mMol) 4-morpholin-4-yl-3-trifluoromethyl-aniline 35 are added, followed by some DMAP. After 16 h, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with sat. Na 2
CO
3
/H
2 O 1:1, H 2 0 and brine, dried (Na 2 SO4) and concentrated.
WO 2007/031265 PCT/EP2006/008857 25 Chromatography (Combi Flash; hexane/EtOAc 4:1 -> 1:9) and crystallization from EtOAc/hexane gives the title compound: MS: [M+1]*= 510; TLC(EtOAc/hexane 2:1): Rf = 0.17; HPLC: ^tRe = 12.5. 5 Example 24: 6-(2-Amino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid cis/trans-(4-isopropyl cyclohexyl)-amide To an ice cooled solution of 180 mg (0.47 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid (Step 15.1) in 5 ml DMF, 69 pl (0.63 mMol) NMM and 118 pl (0.79 mMol) DEPC are added, followed by 133 mg (0.94 mMol) cis/trans-(4-isopropyl-cyclohexyl)-amine 10 [Arzneim. Forsch. 19 (1969), 140]. After 16 h stirring, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2
CI
2 /EtOAc 9:1 -> 3:2) gives the title compound as a cis/trans mixture: MS: [M+1]* = 405; TLC(CH 2
CI
2 /EtOAc 1:1): Rf = 0.18; HPLC: AtRet = 13.6. 15 Example 25: 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (4-f luoro-3 trifluoromethyl-phenyl)-amide To an ice cooled solution of 120 mg (0.43 mMol) 6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid (Step 25.3) in 3 ml DMF, 63 1 d (0.57 mMol) NMM and 107 p1 (0.72 mMol) 20 DEPC are added, followed by 111 pl (0.86 mMol) 4-fluoro-3-trifluoromethyl-aniline. The solution is stirred for 1 h at 0 "C and 5 h at rt. Then it is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 4:1 -> 1:9) and crystallization from hexane gives the title compound: 25 m.p.: 224-225 *C; MS: [M+1 ]* = 443; TLC(EtOAc): Rf = 0.38; HPLC: At ,t = 12.5. The starting material is prepared as follows: Stepn 25.1: 6-(6-Chloro-pjvrimidin-4-vloxy)-naphthalene-1-carboxylic acid 23.6 g (125 mMol) 6-hydroxy-1-naphthoic acid are dissolved in a solution of 10.7 g (265 mMol) 30 NaOH in 125 ml H 2 0. Then 19.8 g (133 mMol) 4,6-dichloro-pyrimidine dissolved in 125 ml acetone are added dropwise during 30 min. The suspension is stirred for 20 h at rt and then partially concentrated in vacuo. The resulting residue is diluted with 600 ml EtOAc and 300 ml H 2 0 and acidified to pH 3 with 4 N HCl. The aqueous layer is separated off and extracted 3 times with EtOAc. The organic phases are washed 3 times with H 2 0 and brine, dried 35 (Na 2
SO
4 ), treeted with char coal and partially concentrated. The resulting suspension is diluted with 400 ml ether, the crystals filtered off and washed with hexane, yielding the title compound: m.p.: 194-195 *C; MS: [M+1 ]* = 301.
WO 2007/031265 PCT/EP2006/008857 26 Step 25.2: 6-(6-Azido-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid To 1.00 g (3.3 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid in 11 ml DMF, 0.43 g (6.6 mMol) NaN 3 are added. After stirring for 2.5 h at 60 *C, the reaction mixture is 5 concentrated in vacuo (40 *C). The residue is dissolved in H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with brine, dried (Na 2
SO
4 ) and concentrated, giving the title compound: MS: [M+1 ]* = 308; H PLC: AtRet = 13.4. More product can be precipitated from the combined aqueous phases by acidifying them with citric acid to pH ~ 2. 10 Step 25.3: 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid 0.49 g (1.6 mMol) 6-(6-azido-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid in 25 ml THF are hydrogenated in the presence of 0.2 g Pd/C (10 %; Engelhard 4505). The partially crystallized product can be isolated by dissolving it in a mixture of MeOH/EtOAc/THF at 40 15 *C, filtration, extensively washing with MeOH/CH 2
C
2 , and concentration of the filtrate: m.p.: 288-290 *C; MS: [M+1]= 282; HPLC: AtRet = 8.6. Alternative method for synthesis of 6-(6-amino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid 1.00 g (3.3 mMol) 6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid and 0.43 g (6.6 20 mMol) NaN 3 are stirred for 2 h at 65 *C in 11 ml DMF. The suspension is cooled to rt, 200 mg Pd/C (10 %; Engelhard 4505) are added and the mixture is hydrogenated for 16 h. The catalyst is filtered off and the filtrate concentrated in vacuo. The residue is re-dissolved in 5 ml DMF and poured into 150 ml H 2 0 and 3 ml 10 % citric acid. Filtration and washing with
H
2 0 gives the title compound. 25 Example 26: 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenyl)-amide To a solution of 11.0 g (39.1 mMol) 6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid, 5.9 ml (47 mMol) 3-trifluoromethyl-aniline, 54 ml (390 mMol) Et 3 N and 2.4 g (19.6 mMol) 30 DMAP in 200 ml DMF, 46 ml (78 mMol) propylphosphonic anhydride are added dropwise. After 2 h, the mixture is concentrated in vacuo and the residue diluted with H 2 0 and EtOAc. The aqueous phase is separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; CH 2 Cl 2 /EtOAc 2:1 -+ 1:1 -+ 1:3) and crystallization from EtOAc gives the title 35 compound: m.p.: 243-244 "C; MS: [M+1]*= 425; HPLC: AtRt = 12.6; Anal.: C,H,N,F.
WO 2007/031265 PCT/EP2006/008857 27 Example 27: 6-(6-Chloro-pyrimidin-4-vloxy)-benzooxazole-3-carboxylic acid (3-trifluoromethyl phenyl)-amide To a solution of 300 mg (0.92 mMol) 6-hydroxy-benzooxazole-3-carboxylic acid (3-trifluoromethyl phenyl)-amide (Step 27.3) and 138 mg (0.92 mMol) 4,6-dichlorpyrimidine in 9 ml acetone, 5 0.92 mi NaOH 1N are added. Then the mixture is stirred for 120 min at 50 *C and concentrated in vacuo. The residue is dissolved in EtOAc and H 2 0, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 85:15 -4 4:1) gives the title compound: MS: [M+1]*= 437; TLC(hexane/EtOAc 1:1): Rf = 0.42; 10 HPLC: ^ter = 15.9. The starting material is prepared as follows: Step 27.1: 1-(4-Benzyloxy-2-hVdroxy-phenyl)-3-(3-trifluoromethVl-phenyl)-urea To a solution of 4.44 g (20.6 mMol) 2-amino-5-benzyloxy-phenol [preparation see: WO 03/045925; 15 page 146] in 90 ml THF, a solution of 3.01 ml (21.9 mMol) 3-trifluoromethyl-phenylisocyanate in 90 ml THF is added dropwise. After 15 h at rt, the reaction mixture is concentrated partially in vacuo, the residue is re-dissolved in H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. The crude product is dissolved in 50 ml boiling EtOAc. Addition 20 of 40 mi hexane and cooling to rt gives the crystalline title compound: m.p.: 184-185 0C; MS: [M+1]*= 403; HPLC: AtRet = 15.3. Step 27.2: 6-Benzvloxy-benzooxazole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide To a solution of 6.80 g (16.9 mMol) of 1-(4-benzyloxy-2-hydroxy-phenyl)-3-(3-trifluoromethyl 25 phenyl)-urea in 100 mi DMF, 11.9 ml (0.17 Mol) dibromo-methane are added, followed by small portions of 19.3 g (59 mMol) of Cs 2
CO
3 . After 10 h at rt, the reaction mixture is concentrated in vacuo and the residue dissolved in EtOAc and a 10 % citric acid solution. The separated aqueous phase is extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. The dark brown oil is dissolved in 30 CH 2
CI
2 /MeOH, then 28 g of SiO 2 are added and the mixture is evaporated. The resulting powder is put on top of a chromatography column (SiO 2 ; hexane/EtOAc 3:1) and the title compound eluated with hexane/EtOAc 3:1 as an oil: MS: [M+1]*= 415; TLC(hexane/EtOAc 1:1): Rf = 0.59; HPLC: AtRet = 17.2. 35 Step 27.3: 6-Hydroxy-benzooxazole-3-carboxylic acid (3-trifluoromethyl-phenvl)-amide As a solution in 60 ml THF, 1.67 g (4.0 mMol) 6-benzyloxy-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide are hydrogenated in the presence of 0.9 g Pd/C (10 %; WO 2007/031265 PCT/EP2006/008857 28 Engelhard 5125). The catalyst is filtered off, washed with THF and the filtrate diluted with hexane. Partial concentration leads to the crystalline title compound, which is filtered off and washed with hexane: m.p.: 173-174 0 C; MS: [M+1]*= 325; HPLC: AtRe, = 13.3. 5 Example 28: 6-(6-Amino-pyrimidin-4-vloxy)-benzooxazole-3-carboxylic acid (3-trifluoromethyl phenyl)-amide 150 mg (0.34 mMol) 6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide and 45 mg (0.69 mMol) NaN 3 in 2 ml DMF are stirred for 5 h at 60 *C giving 6-(6-azido-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (3-trifluoromethyl 10 phenyl)-amide (MS: [M+1]*= 444). After cooling to rt, 35 mg Pd/C (10 %; Engelhard 4505) are added and the mixture is hydrogenated for 30 min. The catalyst is filtered off, washed with DMF and the filtrate concentrated in vacuo. Chromatography (Combi Flash; hexane/EtOAc 1:1 --> EtOAc) gives the title compound: MS: [M+1]*= 418; TLC(EtOAc: Rf 0.25; HPLC: AtRet = 12.0. 15 Example 29: 6-(6-Methylamino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide In a sealed tube, 0.43 mMol of 6-(6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide in 2 ml THF and 2 ml methylamine (2 N in THF) are stirred for 20 16 h at rt. Concentration, chromatography (Combi Flash; CH 2
CI
2 /MeOH 99:1 -> 95:5) and crystallizatione from hexane gives the title compound: MS: [M+1 ]* = 432; TLC(CH 2
CI
2 /MeOH 9:1: Rf = 0.34; HPLC: AtRe = 12.5. Example 30: 6-(2-Amino-6-chloro-pyrimidin-4-vloxy)-benzooxazole-3-carboxylic acid (3 25 trifluoromethyl-phenyl)-amide To an ice cooled solution of 300 mg (0.92 mMol) 6-hydroxy-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide (Step 27.3) and 151 mg (0.92 mMol) 2-amino-4,6 dichlorpyrimidine in 8 ml DMF, 600 mg (1.84 mMol) Cs 2
CO
3 are added. Then the mixture is stirred for 4 h at rt and 1.5 h at 40 C and finally concentrated in vacuo. The residue is 30 dissolved in EtOAc and H 2 0 /brine 1:1. The separated aqueous phase is extracted twice with EtOAc. The organic layers are washed with H 2 0 /brine 1:1 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2
CI
2 /MeOH 99:1 -- + 95:5) gives the title compound: MS: [M+1]*= 452/454; TLC(CH 2 CI2/MeOH 9:1): Rr = 0.51; HPLC: AtRet = 15.3. 35 Example 31: 6-(2-Amino-pyrimidin-4-vloxy)-benzooxazole-3-carboxylic acid (3-trifluoromethyl phenvi)-amide WO 2007/031265 PCT/EP2006/008857 29 Hydrogenation of 38 mg 6-(2-amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide as described in Ex. 14 gives the title compound: MS: [M+1 ]= 418; HPLC: AtRet = 12.5. 5 Example 31A: 6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide To a solution of 650 mg (1.90 mMol) 6-hydroxy-benzooxazole-3-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide in 15 mi acetone, 2.5 ml 1 N NaOHaq are dropped in followed by a solution of 325 mg (2.18 mMol) 4,6-dichlorpyrimidine in 5 ml acetone. After 75 min the 10 reaction mixture is concentrated in vacuo and the residue dissolved in EtOAc, H 2 0 and brine. The aqueous phase is separated off and extracted twice with EtOAc. The organic layers are washed with 2 portions of H 2 0/brine 1:1 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2 Cl 2 /EtOAc 97:3 -4 9:1) gives the title compound: MS: [M+1 1 = 455/457; TLC(CH 2 Cl 2 /EtOAc 9:1): Rf = 0.26; HPLC: AtRet 1 6.3. 15 The starting material is prepared as follows: Step 31A.1: 1-(4-Benzvloxy-2-hydroxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-phenvl)-urea To a solution of 3.01 g (14 mMol) 2-amino-5-benzyloxy-phenol [preparation see: WO 03/045925; page 146] in 60 ml THF, a solution of 2.11 ml (14.8 mMol) 4-fluoro-3-trif luoromethyl 20 phenylisocyanate in 50 ml THF is added dropwise. After 1.5 h at rt, the reaction mixture is concentrated partially in vacuo, the residue is re-dissolved in H 2 0 and EtOAc. The organic layers are separated off and washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated to a volume of ~ 80 ml. Addition of 50 mi hexane gives the crystalline title compound: m.p.: 188 191 0C; MS: [M+1]*= 421; TLC(hexane/EtOAc 1:1): R, = 0.31. 25 Step, 31A.2: 6-Benzvloxy-benzooxazole-3-carboxylic acid (4-fluoro-3-trifluoromethyl-phenvl)-amide 12.5 g (38.3 mMol) Cs2CO3 are added to a solution of 4.6 g (10.9 mMol) 1-(4-benzyloxy-2-hydroxy phenyl)-3-(4-fluoro-3-trifluoromethyl-phenyl)-urea in 100 mi DMF, followed by 7.6 ml (109 mMol) CH 2 Br 2 . This dark green mixture is stirred for 13 h at rt and 70 min at 50 0 C. Then it is 30 concentrated in vacuo and the residue re-dissolved in EtOAc and a 10 % citric acid solution. The separated aqueous phase is extracted twice with EtOAc. The organic layers are washed with 2 portions of H 2 0 and brine, dried (Na 2
SO
4 ) and after addition of SiO 2 concentrated. The resulting powder is put on top of a chromatography column (SiO 2 ) and the title compound eluated with hexane/EtOAc 4:1: m.p.: 144-146 0C; MS: [M-1]= 431; TLC(hexane/EtOAc 1:1): 35 Rt = 0.57. Step 31A.3: 6-Hydroxy-benzooxazole-3-carboxylic acid (4-fluoro-3-trifluoromethyl-phenvl)-amide WO 2007/031265 PCT/EP2006/008857 30 Hydrogenation of 1.69 g (3.91 mMol) 6-benzyloxy-benzooxazole-3-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide in 60 ml THF in the presence of 0.85 g Pd/C (10 %; Engelhard 5125), filtration, partial concentration of the filtrate, dilution with ~ 15 ml hexane and cooling to 0 0C gives the crystalline title compound: m.p.: 171-172 0C; MS: [M-1]= 341; HPLC: At Ret = 5 13.7. Example 31 B: 6-(6-Amino-pvrimidin-4-vloxy)-benzooxazole-3-carboxVlic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide 50 mg (0.11 mMol) 6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (4-fluoro-3 10 trifluoromethyl-phenyl)-amide and 14.3 mg (0.22 mMol) NaN 3 in 1.5 ml DMF are stirred for 5 h at 60 CC giving 6-(6-azido-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (4-fluoro3 trifluoromethyl-phenyl)-amide (MS: [M-1] = 460). After cooling to rt, 13 mg Pd/C (10 %; Engelhard 4505) are added and the mixture is hydrogenated over night. The catalyst is filtered off, washed with DMF and the filtrate concentrated in vacuo. Chromatography (Combi 15 Flash; CH 2
CI
2 /EtOAc 3:2 -> EtOAc) gives the title compound: MS: [M+1]*= 436; TLC(EtOAc: Rf = 0.22; HPLC: AtRet = 12.5. Example 32: 6-(2-Amino-6-chloro-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-4-chloro-phenyl)-amide 20 To an ice cooled solution of 161 mg (0.51 mMol) 6-(2-amino-6-chloro-pyrimidin-4-yloxy) naphthalene-1-carboxylic acid (Step 13.1) in 5 ml DMF, 75 pl (0.68 mMol) NMM and 127 pl (0.85 mMol) DEPC are added, followed by 0.30 g (1.5 mMol) of 2-chloro-5-amino benzotrifluoride and a catalytic amount of DMAP. After 20 h stirring at rt, the solution is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with 25 EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; EtOAc/hexane 2:8 -> 3:7) and partial concentration of the product containing fractions leads to crystallization. Filtration and washing with hexane gives the title compound: MS: [M+1]*= 493/495; HPLC: ^tRt = 16.7. 30 Example 32A: 6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide can be obtained analogous to the route described in Example 32. Example 32B: 6-(2-Amino-pyrimidin-4-vloxy)-benzooxazole-3-carboxylic acid (4-fluoro-3 35 trifluoromethyl-phenyl)-amide can be obtained analogous to the route described in Example 31.
WO 2007/031265 PCT/EP2006/008857 31 Example 33: 6-(2-Amino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-4 chloro-phenyl)-amide A solution of 100 mg (0.20 mMol) 6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-4-chloro-phenyl)-amide in 10 ml THF and 31 pl (0.22 mMol) Et 3 N is 5 hydrogenated in the presence of 40 mg Pd/C (10 %; Engelhard 4505). The catalyst is filtered off, the filtrate concentrated and the residue diluted with EtOAc and H 2 0. The aqueous layer is extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Reversed phase MPLC gives the title compound: MS: [M+1 ]= 459; HPLC: AtRet 13.3. 10 Examples 34 (a)-(b): Via analogous routes the following derivatives can be obtained: N O O (a) N O O (b) N -c 0 O N HN 0 O N FF F Example 35: 6-(2-Amino-pyrimidin-4-vloxy)-naphthalene- 1 -carboxylic acid [4-(4-methyl-piperazin 15 1 -yl-methyl)-3-trifluoromethyl-phenyll-amide To a solution of 50 mg (0.178 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step 15.1) and 53 mg (0.19 mMol) 4-(4-methyl-piperazin-1-yl-methyl)-3-trifluoromethyl aniline in 2 ml DMF, 198 pl (1.42 mMol) Et 3 N, 156 1d (0.267 mMol) propylphosphonic anhydride and 10 mg DMAP are added. After 3 days, the mixture is poured into H 2 0 and 20 EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Reversed phase chromatography and crystallization from DIPE/hexane gives the title compound: MS: [M+1]* = 537; TLC(EtOAc/EtOH/NHa 80:20:1): RI = 0.38; HPLC: AtRet = 9.2; Anal.: C,H,N,F. 25 Example 36: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid [3.4-bis(trifluoromethyl) phenyll-amide To a solution of 100 mg (0.356 mMol) 6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (Step 15.1) and 89.6 mg (0.39 mMol) 3,4-bis(trifluoromethyl)-aniline in 4 ml DMF, 396 1l (2.75 mMol) Et 3 N, 312 pl (0.53 mMol) propylphosphonic anhydride and 10 mg DMAP are 30 added. After 16 h, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; EtOAc/hexane 1:1 -+ EtOAc) gives the title compound: MS: [M+1]* = 493; TLC(EtOAc): Rf = 0.54; HPLC: AtRet = 12.6.
WO 2007/031265 PCT/EP2006/008857 32 Example 37: The following compounds can be obtained analogously to Ex. 35 and 36. O O R1 N ,N N N
NH
2 0 OH NH 2 O N H R2 5 R1 TLC HPLC MS Rf AtRet m.p. [0C] [M+1]* Anal. HN R2 [mini a) 0.71 13.4 483 a)F HN F b) 10.2 411 c) 10.1 411 d) FF .35 13.6 471 F F e) 0.207 13.8 182-184 413 C,H,N f) cI0.433 14.2 210 459/461 F g) 0.44 12.9 217 397 C,H,N h) HN7 0.23 11.2 228 385 C,H,N i) F 0 12.9 236-237 415 j) 0.28 12.3 212 421 C,H,N,F F F k) F 12.9 212213 441 HNO O F STLC(EtOAc); WO 2007/031265 PCT/EP2006/008857 33 2) TLC( hexane/EtOAc 1:3); 3) TLC(EtOAc/CH 2
CI
2 9:1); 4) TLC(EtOAc/CH 2
C
2 4:1); 5) TLC(CH 2
CI
2 /EtOH 19:1) 5 *) 3-cyclopropyl-aniline see: Tet. Lett. 43 (2002), 6987; **) 3-cyclopropyl-4-fluor-aniline prepared from 3-brom-4-fluor-aniline analogously to the procedure described in Tet. Lett. 43 (2002), 6987: TLC(hexane/EtOAc 4:1): Rf = 0.15; ***) 3-(ct,a-difluorethyl)-aniline see: DE2130452 Ex. 12b 10 Example 38: 6-(6-Amino-pyrimidin-4-yloxy)-nap hthalene- 1 -carboxylic acid (3-cyclopropyl-4-fluoro phenyl)-amide To a solution of 267 mg (0.95 mMol) 6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (Step 25.3) and 172 mg (1.14 mMol) 3-cyclopropyl-4-fluor-aniline in 5 ml DMF, 1.32 ml (9.5 mMol) Et 3 N, 1.11 ml (1.9 mMol) propylphosphonic anhydride and 51 mg DMAP are added. 15 After 1 h, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2
CI
2 / EtOH 99:1 -> 19:1) gives the title compound: mp.: 256-257 *C; Anal.: C,H,N,F. 20 Example 39: The following compounds can be obtained analogously to Ex. 38 (eventually longer reaction times necessary).
NH
2 OH-
NH
2 o N O0 OH O NoR H R2 R1 TLC HPLC MS Rf AtRe m.p. [ 0 C] [M+1]* Anal. HN R[min] a) F 0.231 14.1 493 HN F FF b) 0 c' 0.37) 14.0 222-223 459/461 H F WO 2007/031265 PCT/EP2006/008857 34 R1 TLC HPLC MS Rf At Ret m-p- [1 [M-+1j Anal. HN R2 [min] c) 0.281 13.8 272 439 F d) N' 0.40T 9.7 551 HN F N F F e) HN 0.35" 12.5 267 371 C,H,N f) 0.292 13.7 218-219 399 C,H,N HN g) 0.45 14.3 186-187 413 C,H,N HN h) o 0.22 13.6 510 N, HNC'F FF i) HN' 0.284 12.9 246 397 C,H,N ) 0.0937 -- 11.3 251-252 385 C,H,N k) 0.274 12.4 250-251 421 C,H,N,F F F I) 015Y 13.0 239-240 441 C,H,N,F HN01O F TLC(EtOAc/CH 2 Cl 2 1:1); 2) TLC(EtOAc/CH 2 Cl 2 9:1); STLC(EtOAc/EtOH/NH" 80:20:1); 4) TLC(EtOAc/CH 2
C
2 4:1); 5 5) TLC(CH 2
CI
2 /EtOH 19:1) *) 3-cyclopropyl-aniline see: Tet. Lett. 43 (2002), 6987; **) 3-(a,a-difluorethyl)-aniline see: DE2130452 Ex. 12b Example 40: 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (4-morpholin-4-yi 10 3-trifluoromethyl-phenyl)-amide WO 2007/031265 PCT/EP2006/008857 35 To a solution of 295.3 mg (1.00 mMol) 6-(6-methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid and 295 mg (1.2 mMol) 4-morpholin-4-yl-3-trifluoromethyl-aniline in 5 ml DMF, 1.39 ml (10 mMol) Et 3 N, 1.17 ml (2.0 mMol) propylphosphonic anhydride and 50 mg (0.4 mMol) DMAP are added. After 30 min, the mixture is poured into H 2 0 and EtOAc, the 5 aqueous phase separated off and extracted 3 times with EtOAc. The organic layers are washed 3 times with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; CH 2 Cl 2 / EtOH 95:5) gives the title compound: mp.: 156-157 *C; MS: [M+1]*= 524. 10 The starting material is prepared as follows: Step 40.1: 6-(6-Methylamino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid To a solution of 8.1 g (27 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step 25.1) in 100 ml THF, 200 ml of a 2 M solution of methylamin in THF are added. After 3 days at rt, the suspension is concentrated partially in vacuo, the solid filtered off and washed with 15 ether. The crude product dissolved in 300 ml H 2 0 is treated with char coal and filtered. The filtrate is acidified to pH 1 with 1 N HCI and the formed precipitate filtered off, washed with
H
2 0 and dried. Repeated stirring in ether followed by filtration gives the title compound: m.p.: 267-268 *C; MS: [M+1]'= 296. 20 Example 41: The following compounds can be obtained analogously to Ex. 40. N O N OR1 NH c?9 rNHq 0 OH NNH 0 H R2 R1 TLC HPLC MS R AtRet m.p. [C) [M+1)+ Anal. HN R2 ] a) 0.29') 11.7 152-153 439 H F b) F 0.26' 11.9 154-155 457 F F c) 0.22F 12.5 102-104 427 WO 2007/031265 PCT/EP2006/008857 36 R1 TLC HPLC MS Rf AtRd m.p. ["C] [M+1]* Anal. HN R2 [min] d) 0.30 12.6 141-142 427 e) H c' O.227 12.5 148-149 473/475 H F f) 2 12.2 238-239 453 H F g) N 0.23'T- 8.5 551 F F h) F .2'- 12.3 211-212 497 F'F I-F h) HN 4T i) 0.51P 12.7 144-145 411 CH,N j) H 12.6 164 385 k) 0.2941 12.0 128-129 413 C,H,N HN 0.254 11.6 160-161 399 C,H,N 0 TLC(CH 2
CI
2 /MeOH 19:1); 2) TLC(CH 2 Cl 2 /MeOH/NH 3 ' 90:10:1); 3) TLC(CH 2
CI
2 /acetone 2:1); 4) TLC(CH 2
CI
2 /EtOH 19:1) 5 *) 3-cyclopropyl-aniline see: Tet. Lett. 43 (2002), 6987 Example 42: 6-(6-Chloro-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenvi)-amide To 8.38 g (27.9 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step 25.1), 31 10 ml (223 mMol) Et 3 N and 1 g (8 mMol) DMAP in 100 ml ice-cooled DMF, 24.4 ml (41.8 mMol) propylphosphonic anhydride in 25 ml DMF are added dropwise during 20 min, followed by a solution of 3.83 ml (30.6 mMol) 3-trifluormethyl-aniline in 25 ml DMF. After 90 min at rt, the mixture is concentrated partially in vacuo at 40 *C. The resulting residue is diluted with H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic WO 2007/031265 PCT/EP2006/008857 37 layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; CH 2
CI
2 / THF 99:1 -> CH 2
CI
2 / THF/Et 3 N 98:1:1) gives the title compound: MS: [M+1]*= 444; TLC(CH 2
CI
2 / THF 99:1): Rf = 0.17; HPLC: Atne, = 16.8. 5 Example 43: 6-(6-Cyano-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenyl)-amide To a solution of 3.3 g (7.4 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-phenyl)-amide in 80 ml DMSO and 20 ml H 2 0, 0.42 g (3.7 mMol) 1,4 diazobicyclo[2,2,2]octan and 1.0 g (15 mMol) KCN are added. The mixture is stirred for 30 10 min at 55 0C and then diluted with H 2 0, brine and EtOAc. The aqueous phase is separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (MgSO 4 ) and concentrated. The residue is re-dissolved in CH 2 Cl 2 and after addition of SiO 2 concentrated again. The resulting powder is put on top of a SiO 2 -column. Eluation with
CH
2
CI
2 / EtOAc 98:2 -+ 93:7, partial concentration and crystallization by adding hexane gives 15 the title compound: m.p.: 167 0C; MS: [M+1]+= 435; Anal.: C,H,N,F. Example 44: 6-(6-Aminomethyl-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-phenvl)-amide 830 mg (1.91 mMol) 6-(6-cyano-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3 20 trifluoromethyl-phenyl)-amide in 40 ml THF and 7.3 ml NH 3 aq 25 % are hydrogenated in presence of 0.7 g Raney-Nickel (Degussa B 113W). The aqueous layer is separeted off from the reaction mixture and extracted with EtOAc. The organic phases are dried (Na 2
SO
4 ) and concentrated. This residue is re-dissolved in EtOAc/acetone and after addition of SiO 2 concentrated again. The resulting powder is put on top of a SiO 2 -column. Eluation with 25 EtOAc/acetone/Et 3 N 80:20:0 -> 80:20:1 -4 60:40:1, partial concentration and crystallization by adding hexane gives the title compound: MS: [M+1]*= 439; TLC(EtOAc/acetone 2:1 +
NH
3 aq): Rt = 0.35; HPLC: AtReet = 12.5. Example 45: {6-[5-(3-Trifluoromethyl-phenvlcarbamol)-naphthalen-2-loxyl-pyrimidin-4-lmethyl} 30 carbamic acid methylester A mixture of 100 mg (0.23 mMol) 6-(6-aminomethyl-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide, 175 pl (1.2 mMol) Et 3 N, 60 pl (0.77 mMol) methyl chloroformate and a trace of DMAP in 3 ml THF is stirred over night at rt. The mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with 35 EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Rash; hexane/ EtOAc 7:3 -+ 1:1) gives the title compound: MS: [M+1]*= 497; TLC(EtOAc/hexane 2:1): Rf = 0.35; HPLC: AtRet = 14.9.
WO 2007/031265 PCT/EP2006/008857 38 Example 46: 6-[5-(3-Trifluoromethyl-phenvlcarbamovl)-naphthalen-2-vloxyl-pyrimidine-4-carboxylic acid ethyl ester A mixture of 5.36 g (12.07 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3 5 trifluoromethyl-phenyl)-amide (Ex. 43), 3.4 ml (24 mMol) Et 3 N and 1.35 g PdC 2
[P(C
6
H
5
)
3
]
2 in 80 ml ethanol is prepared under a CO-atmosphere of 120 bar in an autoclave. Then it is heated for 30 h at 110 *C. After cooling to rt, the mixture is diluted with EtOH and filtered. The residue is washed vigorously with EtOH and the filtrate concentrated. Column chromatography (SiO 2 ; CH 2
C
2 /EtOAc 19:1 -4 9:1) and partial concentration leads to the 10 crystalline title compound: m.p.: 194 *C; Anal.: C,H,N,F. Example 47: 6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-Vloxyl-pyrimidine-4-carboxylic acid To 0.36 g (0.75 mMol) 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4 15 carboxylic acid ethyl ester dissolved in 9 ml THF, 1.15 ml 1 M LiOH in H 2 0 are added. After 2 h at rt, the mixture is concentrated in vacuo. The residue is dissolved in a mixture of EtOAc,
H
2 0 and 1 N NaOH-solution. The aqueous layer is separated off and extracted with EtOAc. The organic phases are washed with a diluted NaOH-solution and discarded. The combined aqueous layers are acidified with 2 N HCI and extracted twice with EtOAc. These organic 20 phases are washed with brine, dried (Na 2
SO
4 ) and concentrated. Crystallization from DIPE gives the title compound: MS: [M+1 ]* = 454. Example 48: 6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxyl-pyrimidine-4-carboxylic acid dimethylamide 25 To 200 mg (0.435 mMol) of the lithium-salt of 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen 2-yloxy]-pyrimidine-4-carboxylic acid, 612 pl (4.4 mMol) Et 3 N, 24 mg (0.2 mMol) DMAP and 24 mg (0.53 mMol) Me 2 NH in 7 ml DMF, 516 II (0.88 mMol) propylphosphonic anhydride are added. After 2.5 h at rt, the mixture is diluted with H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and 30 brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; hexane/EtOAc 3:2 -4 2:3) gives the title compound: MS: [M+1J= 481; TLC(CH 2
CI
2 /EtOAc 1:1): Rf = 0.18; HPLC: AtRet = 15.8. Example 49: 6-[5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-vloxyl-pyrimidine-4-carboxylic 35 acid amide To a solution of 207 mg (0.43 mMol) 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy] pyrimidine-4-carboxylic acid ethyl ester (Ex. 47) in 12 ml CH 3 CN and 5 ml THF, 5 ml of NH 3 WO 2007/031265 PCT/EP2006/008857 39 (25 % in H 2 0) are added. This mixture is stirred in a sealed vessel for 7 h at rt, while a precipitation is formed. Filtration and washing with CH 3 CN yields the title compound: MS: [M 1]= 451; HPLC: AtRet = 15.2; Anal.: C,H,N,F. 5 Example 50: 6-[5-(3-Trifluoromethyl-phenvlcarbamovl)-naphthalen-2-vloxyl-pyrimidine-4-carboxvlic acid methylamide To 200 mg (0.435 mMol) of the lithium-salt of 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen 2-yloxy]-pyrimidine-4-carboxylic acid, 609 [d (4.35 mMol) Et 3 N, 24 mg (0.2 mMol) DMAP and 260 pl (2 M in THF; 0.52 mMol) MeNH 2 in 7 ml DMF, 510 gI (0.87 mMol) propylphosphonic 10 anhydride are added. After 1 h at rt, the mixture is diluted with H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed twice with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash;
CH
2 CI2/EtOAc 4:1) gives the title compound: MS: [M+1]*= 467; TLC(EtOAc): Rf = 0.55; HPLC: AtRet = 15.7. 15 Example 51: 6-[5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-yloxyl-pyrimidine-4-carboxylic acid isopropylamide To a solution of 197 mg (0.41 mMol) 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy] pyrimidine-4-carboxylic acid ethyl ester (Ex. 47) in 10 ml THF, 7 il (0.4 mMol) H 2 0 and 0.7 20 ml (8 mMol) isopropylamine are added. This mixture is stirred in a sealed vessel for 5 days at 45 *C. Reversed phase chromatography gives the title compound: m.p.: 205-208 *C; MS: [M+1]*= 495; Anal.: C,H,N,F. Example 52: 6-(6-Hydroxymethyl-rpvrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3 25 trifluoromethyl-phenvl)-amide To 1.16 g (2.41 mMol) 6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4 carboxylic acid ethyl ester (Ex. 47) in 40 ml tert-butanol, 218 mg (5.76 mMol) NaBH 4 are added and the mixture is stirred for 1 h at 70 0C. Then additional 109 mg NaBH 4 are added and stirring is continued for another 1 h at 80 *C. The reaction mixture is concentrated in 30 vacuo and the residue re-dissolved in EtOAc and sat. NaHCO 3 . The separated aqueous phase is extracted twice with EtOAc. The organic layers are washed with sat. NaHCO 3 and brine, dried (Na 2
SO
4 ) and concentrated after addition of SiO 2 . This powder is put on top of a SiO 2 -column (CH 2 CI2/EtOAc 2:1 -> 1:1 -+ EtOAc): At first the side product 6-(6-methyl pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide is eluated 35 {MS: [M+1]*= 424; TLC(CH 2 Cl 2 /EtOAc 1:1): Rt = 0.33; HPLC: AtRet = 15.1), followed by the title compound: m.p.: 183-184 *C; MS: [M+1 ]= 440; TLC(CH 2
CI
2 /EtOAc 1:1): R, = 0.13; HPLC: AtRe = 14.3; Anal.: C,H,N,F.
WO 2007/031265 PCT/EP2006/008857 40 Example 53: 6-(6-Chloromethyl-pvrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (3 trifluoromethyl-phenvl)-amide 1.0 ml (13.9 mMol) SOC1 2 is added via syringe to a solution of 610 mg (1.39 mMol) 6-(6 5 hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl) amide in 50 ml CH 3 CN and 10 ml THF. After 15 min at rt, the solution is poured into 75 ml sat. NaHCO 3 and 75 ml H 2 0 and then concentrated partially in vacuo. The formed precipitate is filtered off and washed with H 2 0, yielding the title compound: m.p.: 178-181 *C; MS: [M+1]*= 458/460; Anal.: C,H,N,F. 10 Example 54: 6-(6-Methylaminomethyl-pvrimidin-4-vloxy)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide In a sealed tube a mixture of 150 mg (0.328 mMol) 6-(6-chloromethyl-pyrimidin-4-yloxy) naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, 10 mg (0.067 mMol) Nal and 15 0.8 ml methylamine (2 M in THF) in 8 ml THF is stirred for 2.5 h at 80 0C. The reaction mixture is concentrated in vacuo and the residue re-dissolved in EtOAc and sat. NaHCO 3
/H
2 0 1:1. The separated aqueous phase is extracted twice with EtOAc. The organic layers are washed with sat. NaHCO 3
/H
2 0 1:1 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; EtOAc/(THF + 2 % EtN) 19:1 -- + 1:1) gives the title 20 compound: m.p.: 141-143 "C; MS: [M+1]*= 453; Anal.: C,H,N. Example 55: 6-(6-Dimethylaminomethyl-pyrimidin-4-vloxy)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide In a sealed tube a mixture of 150 mg (0.328 mMol) 6-(6-chloromethyl-pyrimidin-4-yloxy) 25 naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide, 134 mg (1.64 mMol) dimethylamine hydrochloride, 10 mg (0.067 mMol) Nal, 687 pl (4.9 mMol) Et 3 N and 8 ml THF is stirred for 4.25 h at 80 "C. Work up analogously as described for Ex. 54 gives the title compound: m.p.: 180-181 *C; MS: [M+1]*= 467; Anal.: C,H,N,F. 30 Example 56: {6-[5-(4-Fluoro-3-trifluoromethyl-phenvlcarbamovl)-naphthalen-2-lsulfanyl]-pyrimidin 4-vil-carbamic acid tert-butyl ester To an ice-cooled solution of 127 mg (0.32 mMol) 6-(6-tert-butoxycarbonylamino-pyrimidin-4 ylsulfanyl)-naphthalene-1 -carboxylic acid (Step 57.2) and 86 mg (0.48 mMol) 4-f luoro-3 trifluoromethyl-aniline in 3 ml DMF, 446 pl (3.2 mMol) Et 3 N, 0.37 ml (0.63 mMol) 35 propylphosphonic anhydride and 4 mg DMAP are added. After 2 h at rt, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed twice with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Re- WO 2007/031265 PCT/EP2006/008857 41 crystallization from boiling CH 3 CN gives the title compound: MS: [M+1]*= 559; TLC(hexane/EtOAc 1:1): Rf = 0.47; Anal.: C,H,N,F. The starting material is prepared as follows: 5 Step 56.1: 6-(6-Chloro-pyrimidin-4-vlsulfanyl)-naphthalene-1 -carboxylic acid 894 mg (6.0 mMol) 4,6-Dichloro-pyrimidine and 1021 mg (5.0 mMol) 6-mercapto-naphthalene-1 carboxylic acid [preparation described in J. Med. Chem. 32 (1989), 2493; purification by chromatography (Combi Flash; hexane/EtOAc 7:3 -> 3:2): m.p.: 212-213 *C] are suspended in 16 ml acetone. Then 16 ml of 1 N NaOH in H 2 0 are added. After 5 min at rt, the resulting 10 solution is poured into 200 ml of 1 N HCl in H 2 0 and extracted 3 times with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; CH 2 Cl 2 /EtOAc 1:2) and crystallization from EtOAc/hexane yields the title compound: m.p.: 209 0C; MS: [M-1]= 317. 15 Step 56.2: 6-(6-tert-Butoxvcarbonylamino-pvrimidin-4-vlsulfanyl)-naphthalene-1-carboxylic acid A suspension of 195 mg (0.61 mMol) 6-(6-chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1 -carboxylic acid and 495 mg (1.52 mMol) Cs 2
CO
3 in 5 ml dioxane is degassed repeatedly by evaporation and flushing with N 2 . Then 10.9 mg (0.019 mMol) 4,5-bis(diphenylphosphino)-9,9 dimethylxanthene, 5.6 mg (0.006 mMol) tris(dibenzylidenaceton)dipalladium (0) CHC 3 20 adduct and 85.8 mg (0.73 mMol) carbamic acid tert-buty ester are added successively. After 4 h stirring at 110 *C, another 10.9 mg 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 5.6 mg tris(dibenzylidenaceton)dipalladium (0) CHCl 3 adduct are added and stirring is continued for 5 h. Then the cooled mixture is poured into EtOAc and 5 % citric acid in H 2 0, the aqueous layer separated off and extracted twice with EtOAc. The organic layers are 25 washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2 Cl 2 /EtOAc 99:1 -> CH 2 Cl 2 /(EtOAc + 1 % HOAc) 4:1) gives the title compound: m.p.: 208-209 *C; MS: [M-1] = 396. Example 57: 6-(6-Amino-pyrimidin-4-vlsulfanyl)-naphthalene-1 -carboxylic acid (4-f luoro-3 30 trifluoromethyl-phenvl)-amide To a solution of 80 mg (0.14 mMol) {6-[5-(4-fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen 2-ylsulfanyl]-pyrimidin-4-yl}-carbamic acid tert-butyl ester in 2 ml dioxane are added 2 ml 2 M HCI in dioxane. After 9 h at rt, the solution is diluted with EtOAc and sat. NaHCO 3
/H
2 0 1:1. The aqueous phase is separated off and extracted twice with EtOAc. The organic layers are 35 washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash; CH 2 Cl 2 /EtOAc 4:1 -4 1:4) and crystallization from EtOAc/hexane gives the title compound: m.p.: 221 0C; MS: [M+ 1]*= 459; TLC(CH 2
CI
2 /EtOAc 1:2): Rf = 0.25.
WO 2007/031265 PCT/EP2006/008857 42 Example 58: 6-(6-Amino-pvrimidin-4-vlsulfanyl)-nap~hthalene-1 -carboxylic acid (3-trifluoromethyl phenyl)-amide To 1.65 g (5.55 mMol) 6-(amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid, 832 pl (6.66 5 mMol) 3-trifluoromethyl-aniline, 7.87 ml (56.5 mMol) Et 3 N and 291 mg (2.38 mMol) DMAP in 30 ml DMF, 6.8 ml (11.6 mMol) propylphosphonic anhydride are added dropwise. After 1 h at rt, the mixture is poured into H 2 0 and EtOAc, the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated after addition of SiC 2 . The resulting powder is put on top of a SiO 2 column 10 (CH 2 Cl 2 /EtOAc 9:1) and the title compound eluted with CH 2
CI
2 /EtOAc 4:1 -> 3:7: m.p.: 205 *C; MS: [M+ 1]*= 441; TLC(CH 2 Cl 2 /EtOAc 1:1): R = 0.16; HPLC: AtRef = 13.0. The starting material is prepared as follows: Step 58.1: 6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid 15 A mixture of 1.00 g (7.72 mMol) 4-amino-6-chloro-pyrimidine, 1.74 g (8.5 mMol) 6-mercapto naphthalene-1 -carboxylic acid, 10.8 g K 3 P0 4 and 35 mg (0.23 mMol) Nal in 50 ml NMP is stirred for 2.5 h at 110 *C. Then the mixture is poured into 230 ml of a 5 % solution of citric acid in H 2 0, the crude product filtered off and washed with H 2 0. Stirring in boiling isopropanol and filtration gives the title compound: m.p.: 264-266 0C; MS: [M+1]*= 298. 20 Example 59: 6-(6-Amino-pyrimidine-4-sulfinyl)-naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)-amide Example 60: 6-(6-Amino-pyrimidine-4-sulfonyl)-naphthalene-1-carboxylic acid (3-trifluoromethyl 25 phenyl)-amide Example 61: 6-(6-Amino-pVrimidin-4-vlsulfanyl)-naphthalene-1 -carboxVlic acid (3-trifluoromethoxy phenyl)-amide To 95 mg (0.32 mMol) 6-(amino-pyrimidin-4-ylsulfanyl)-naphthalene-1 -carboxylic acid, 85 mg (0.48 30 mMol) 3-trifluoromethoxy-aniline, 446 pl (3.2 mMol) Et 3 N and 4 mg (0.03 mMol) DMAP in 3 ml DMF, 0.37 ml (0.63 mMol) propylphosphonic anhydride are added. After 3 h at rt, the reaction mixture is worked up as described for Ex. 58, yielding the title compound: m.p.: 197 199 0C; MS: [M+1]= 457. 35 Example 62: 6-(Pyridin-4-yl-methyl)-naphthalene-1 -carboxylic acid (4-fluoro-3-trif luoromethyl phenyl)-amide WO 2007/031265 PCT/EP2006/008857 43 A mixture of 22.4 mg (0.10 mMol) Pd(O 2
CCH
3
)
2 , 52.6 mg (0.20 mMol) triphenylphosphine, 151 mg (0.33 mMol) 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-naphthalene-1-carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and 229.3 mg (1.08 mMol) K 3 P0 4 in 3 ml toluene is degassed repeatedly by evaporation and flushing with N 2 . Then 59 mg (0.36 mMol) 4 5 chloromethyl-pyridine hydrochloride are added and the mixture is stirred at 80 *C for 20 h, when additional 18.5 mg (0.082 mMol) Pd(O 2
CCH
3
)
2 and 43.1 mg (0.164 mMol) triphenylphosphine are added. After 3 h at 110 "C the reaction mixture is poured into H 2 0 and EtOAc. The aqueous phase is separated off and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. 10 Chromatography [Combi Flash; CH 2 Cl 2 - CH 2
CI
2 /(MeOH + 10 % NH 3 aq) 9:1) gives the title compound: MS: [M+1]I= 425; HPLC: AtRet= 12.7. The starting material is prepared as follows: Step 62.1: Trifluoro-methanesulfonic acid 5-(4-fluoro-3-trifluoromethyl-phenylcarbamoyl) 15 naphthalen-2-vl ester 0.94 g (5.0 mMol) 6-hydroxy-naphthalene-1-carboxylic acid in a mixture of 50 ml CH 2 Cl 2 , 25 ml dioxane and 2.4 ml (30 mMol) pyridine is cooled to -78 *C. Then a solution of 1.98 ml (12 mMol) trifluoro-methanesulfonic acid anhydride in 5 ml CH 2
CI
2 is added dropwise and the mixture is warmed up to rt. After 5 h, 1.43 g ( 8.0 mMol) 4-fluoro-3-trifluoro-aniline dissolved 20 in 5 ml CH 2
CI
2 are added and stirring is continued over night. A formed precipitate is filtered off and discarded and the filtrate diluted with EtOAc and sat. NaHCO 3
/H
2 0 1:1. The aqueous phase is separated and extracted twice with EtOAc. The organic layers are washed with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; toluene/EtOAc 199:1 -+ 9:1) and partial concentration leads to the crystalline title compound: m.p.: 171-172 25 *C; MS: [M-1] = 480. Step 62.2: 6-(4,4,5,5-Tetramethvl-[1,3,21dioxaborolan-2-yl)-naphthalene-1 -carboxylic acid (4-f luoro 3-trifluoromethyl-phenvl)-amide A mixture of 1.203 g (2.5 mMol) trifluoro-methanesulfonic acid 5-(4-fluoro-3-trifluoromethyl 30 phenylcarbamoyl)-naphthalen-2-y ester, 762 mg (3.0 mMol) 4,4,5,5,4',4',5',5'-octamethyl [2,2']bi[[1,3,2]dioxaborolanyl] and 736 mg (7.5 mMol) potassium acetate in 12 ml DMF is degassed repeatedly by evaporation and flushing with N 2 . Then 100 mg (0.12 mMol) of the dichloromethane complex of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(li) are added and the mixture is stirred for 3 h at 80 *C. The mixture is diluted with EtOAc and H 2 0, 35 the aqueous phase separated off and extracted twice with EtOAc. The organic layers are washed twice with H 2 0 and brine, dried (Na 2
SO
4 ) and concentrated. Chromatography (Combi Flash: CH 2 Cl2/hexane 1:1; crude product added as solution in CH 2
CI
2 onto WO 2007/031265 PCT/EP2006/008857 44 preconditioned column and rapidly eluated with CH 2
CI
2 /hexane 1:1 -4 CH 2 Cl 2 ) gives the title compound: MS: [M+1]*= 460; TLC(CH 2
CI
2 ): Rf = 0.30; HPLC: AtRet = 18.3. Example 63: 6-(2-Methyl-pyridin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl) 5 amide To a solution of 331 mg (1.0 mmol) 6-hydroxy-naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)-amide in o.375 mL DMF and 1.37 mL DMPU (dimethyl-propylene urea) is added 4 chloro-2-methyl-pyridine (180 mg, 1.1 mmol) followed by potassium t-butoxide (336 mg, 3 mmol). The dark viscous mixture is stirred 3 days at 100 *C. After cooling to rt the mixture is 10 diluted with ethyl acetate, washed with brine, dried over sodium sulfate and evaporated. The remaining DMPU and DMF is distilled off in a Kugelrohr apparatus (100 *C, under vacuum). The residue is purified by flash-chromatography on a silica gel column and eluting with ethyl acetate. Concentration of the pure samples leads to crystalline title compound: MS: [M+1 ]= 423; TLC(ethyl acetate): Rt = 0.5; HPLC: EtRet = 3.42. 15 The starting material is prepared as follows: Step 63.1: 6-hydroxy-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide To an ice-cooled solution of 17.2 g (65 mmol) 6-hydroxy-naphthalene-1-carboxylic and 9.9 g (65 mmol) HOBT in 260 mL of THF is added dropwise a solution of 14.4 g (70.2 mmol) DCC in 20 45 mL of THF over 20 minutes. The reaction mixture is stirred 15 minutes at 0 0 C and then 1 hour at rt. The solid formed is removed by filtration and washed with a small amount of cold THF. The filtrate is evaporated and the residue triturated with ethyl acetate/hexanes 4:6. The crystalline activated ester was filtered off and dried. 9.15 g of this active ester (30 mmol) are dissolved in 80 mL of THF and treated with 3.5 mL (30 mmol) 3-trifluoromethyl-anilin. After 25 refluxing for 24 h another 0.35 mL (3 mmol) 3-trifluoromethyl-anilin is added and the mixture ref luxed for another 24 h. The solvent is removed and the residue subjected to a flash chromatography on silica gel using ethyl acetate/hexanes 4:6. Pure fractions are evaporated and the residue is triturated with petrol ether. The crystalline title compound is filtered and dried: MS: [M+1 ]* = 332; TLC(ethyl acetate/hexanes 4:6): Rf = 0.53; HPLC: Et et = 3.8. 30 Example 64: 4-[5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-vloxy]-pyridine-2-carboxylic acid butyl ester A mixture of 993 mg (3.0 mmol) 6-hydroxy-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenyl)-amide, 10 mL n-BuOH, 1.286 g (7.5 mmol) 4-chloro-pyridine-2-carboxylic acid 35 methyl ester, 0.5 mL (3.6 mmol) triethylamin and 10 mg 4-edimethylamino-pyridine is heated under ref lux for 5 days. After cooling the mixture is evaporated, diluted with ethyl acetate and washed with diluted hydrochloric acid. The ethyl acetate phase is dried with sodium sulfate, WO 2007/031265 PCT/EP2006/008857 45 concentrated and the residue is purified by flash-chromatography on a silica gel column eluting with ethyl acetate/hexanes 4:6. Evaporation of the pure samples leads to crystalline title compound: m.p. 128-130 0C; MS: [M+1]*= 509; TLC(ethyl acetate): Rf = 0.27; HPLC: EtRet = 4.57. 5 Example 65: 4-[5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-vloxyl-pyridine-2-carboxylic acid methylamide 4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-carboxylic acid butyl ester (101 mg, 0.2 mmol) and 1.0 mL of a 33% methylamine solution in ethanol are heated for 1 h 10 under reflux. The mixture is cooled, concentrated and the residue is purified by flash chromatography on a silica gel column eluting with ethyl acetate/hexanes 6:4. Evaporation of the pure samples leads to crystalline title compound: m.p. 175-177 'C; MS: [M+1]*= 466; HPLC: EtRet = 4.18. 15 Using the same procedure as for the previous example the following compounds were synthesized: Example 66: 4-[5-(3-Trifluoromethyl-phenvlcarbamovl)-naphthalen-2-loxyl-pvridine-2-carboxylic acid amide 20 The title compound is obtained as a solid: m.p. 117-120 *C; MS: [M+1]*= 452; TLC(ethyl acetate/hexanes 6:4): R, = 0.3; HPLC: EtRet = 3.91. Example 67: 4-[5-(3-Trifluoromethyl-phenvlcarbamovl)-naphthalen-2-vloxyl-pyridine-2-carboxylic acid (2-dimethylamino-ethyl)-amide 25 The title compound is obtained as a solid: m.p. 80-82 *C; MS: [M+1]*= 523; TLC (dichloromethane/ethanol 9:1 and 1% conc. ammonia): Rf = 0.3; HPLC: EtRet = 3.46. Example 68: 6-(2-Amino-pyridin-4-vloxy)-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl) amide 30 A solution of 60 mg (0.11 mmol) {4-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy] pyridin-2-yl}-carbamic acid tert-butyl ester in 1 mL dioxane is added a 4N hydrochloric acid solution in dioxane (30 pL, 0.13 mmol) and the resulting solution heated under reflux for 8 h. The dioxane is evaporated and the residue partitioned between ethyl acetate and saturated sodium bicarbonate solution. The aqueous phase was extracted twice wit ethyl acetate. The 35 combined ethyl acetate pahses are washed with brine, dried with sodium sulfate and evaporated. The residue is purified by flash-chromatography on a silica gel column eluting with dichloromethane/ethanol 95:5 containing 1% conc. ammonia. Evaporation of the pure WO 2007/031265 PCT/EP2006/008857 46 samples leads to crystalline title compound: m.p. 222-224 *C; MS: [M+1]*= 424; TLC (dichloromethane/ethanol 95:5 and 1% conc. ammonia): R, = 0.3; HPLC: Et r = 3.46. The starting material is prepared as follows: 5 Step 68.1: f4-f5-(3-Trifluoromethyl-phenvlcarbamoyl)-napjhthalen-2-yloxyl-pyridin-2-yl}-carbamic acid tert-butyl ester A mixture of 113 mg (0.25 mmol) 4-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy] pyridine-2-carboxylic acid, 1.5 mL tert.-butanol 0.07 mL (0.3 mmol) phosphorazidic acid diphenyl ester and 0.04 mL (0.03 mmol) triethylamine is heated under reflux for 4 h. The 10 solvent is evaporated, the residue taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and brine, dried with sodium sulfate and concentrated again. The residue is purified by flash-chromatography on a silica gel column eluting with ethyl acetate/hexanes 4:6. Evaporation of the pure samples leads to the title compound: MS: [M+1]*= 524; TLC (ethyl acetate/hexanes 4:6): R, = 0.35; HPLC: ERet = 4.07. 15 Step 68.2: 4-[5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-vloxyl-pyridine-2-carboxylic acid 4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-carboxylic acid butyl ester (165 mg, 0.32 mmol) is dissolved in 6 mL of ethanol and treated with 0.34 mL 1 N sodium hydroxide solution. The suspension is heated for 2 h under reflux, cooled and the solvent 20 evaporated. The residue is triturated with ethyl acetate and filtered. The solid is taken up in a small amaont of H 2 0 and acidified with 2N hydrochloric acid (pH -5). Extraction with ethyl acetate followed by drying of the ethyl acetate extracts with sodium sulfate and evaporation of the solvent gives pure title compound: MS: [M+1J= 453; TLC (ethyl acetate/hexanes 4:6): Rf = 0.35; HPLC: Etiet = 3.29. 25 Example 69: f4-f5-(3-Trifluoromethyl-phenvlcarbamoyl)-naphthalen-2-vloxyl-pyridin-2-yl}-carbamic acid methyl ester To a mixture of 42 mg (0.1 mmol) 6-(2-amino-pyridin-4-yloxy)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide and 16 pL (0.12 mmol) triethylamine in 1 mL of THF are added 30 10 pL (0.12 mmol) of methyl chloroformate at rt. After stirring for 1 h at rt the mixture is diluted with ethyl acetate. This is then washed with saturated sodium bicarbonate solution and brine, dried with sodium sulfate and evaporated. The residue is purified by flash chromatography on a silica gel column eluting with ethyl acetate/hexanes 1:1. After a second chromatography of the enriched fractions, the pure title compound is obtained as a solid: 35 m.p. 230-232 *C; MS: [M+1]*= 482; TLC (ethyl acetate/hexanes 1:1): Rf = 0.45; HPLC: EtR& = 3.69.
WO 2007/031265 PCT/EP2006/008857 47 Example 70: 6-[2-(2-Amino-pvrimidin-4-yl)-ethyll-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenvl)-amide 6-(2-Amino-6-chloro-pyrimidin-4-ylethynyl)-naphthalene-1 -carboxylic acid (3-trifluoromethyl phenyl)-amide (0.069 g, 0.148 mmol) is hydrogenated in the presence of 12 mg of 5 magnesium oxide and 20 mg 10% palladium on carbon in 5 mL of THF at rt. After 48 h the catalyst was filtered off and the filtrate evaporated. The residue is chromatographed on a 4 g silica gel column on a Combi-Flash CompanionTM (Isco Inc.) apparatus using a gradient of 20% ->100% ethyl acetate in hexanes as solvent. The title compound is obtained as a colorless solid: m.p. 225-227 "C; MS: [M+1]*= 435; TLC (ethyl acetate): Rf = 0.25; HPLC: 10 EtRet= 3.43. The starting material is prepared as follows: Step 70.1: 6-(2-Amino-6-chloro-pyrimidin-4-vlethynyl)-naphthalene-1-carboxylic acid (3 trifluoromethyl-phenyl)-amide 15 Nitrogen is passed through a solution of 130 mg (0.383 mmol) 6-ethynyl-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide and 57 mg (0.348 mmol) 2-amino-4,6-dichloro pyrimidine in 1.3 mL DMF. After 10 to 15 minutes, copper (1) iodide (3.5 mg (0.0184 mmol), bis-(triphenylphosphine)-palladium dichloride (17.4 mg, 0.0248 mmol) and triethylamine (52.2 pL, 0.375 mmol) is added and the mixture stirred at rt and under a nitrogen atmosphere for 20 16 h. The DMF is removed under reduced pressure and the residue is chromatographed on a 12 g silica gel column on a Combi-Flash CompanionTM (Isco Inc.) apparatus using a gradient of 0% -- + 50% ethyl acetate in hexanes as solvent. The title compound is obtained as a colorless solid: m.p. 171-175 *C; MS: [M+1 ]* = 465, 467; TLC (ethyl acetate/hexanes 1:1): Rf = 0.31; HPLC: EtRet = 4.74. 25 Step 70.2: 6-Ethynyl-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide 6-Trimethylsilanylethynyl-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide (0.194 g, 0.47 mmol) is dissolved in 3.8 mL of methanol at rt. After the addition of potassium carbonate 0.1 g (0.724 mmol) the mixture is stirred for 16 at rt. The solvent was removed and the 30 residue partitioned between 10 mL of ethyl acetate and 5 mL of H 2 0. The organic phase is washed with brine, dried with sodium sulfate and evaporated. The title compound is obtained as a brown resin: MS: [M+1 ]* = 340;HPLC: EtRet = 4.58. Step 70.3: 6-Trimethylsilanylethynyl-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl) 35 amide Trifluoro-methanesulfonic acid 5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-y ester (0.695 g (1.5 mmol), copper (1) iodide (0.015 g, 0.079 mmol) and bis-(triphenylphosphine)-palladium WO 2007/031265 PCT/EP2006/008857 48 dichloride (17.4 mg, 0.0248 mmol) are mixed in a Schlenk apparatus under nitrogen and treated at rt with a carefully degassed solution of 0.233 mL (1.65 mmol) ethinyl trimethylsilane and 0.225 mL (1.62 mmol) triethylamine in 5.6 mL dry DMF. The clear dark solution is kept at rt for 16 h and then the DMF is evaporated under reduced pressure. The 5 residue is chromatographed on a 40 g silica gel column on a Combi-Flash CompanionTM (Isco Inc.) apparatus using a gradient of 0% -- > 20% ethyl acetate in hexanes as solvent. The title compound is obtained as a tan solid: m.p. 134-136 *C; MS: [M+1]*= 412; TLC (ethyl acetate/hexanes 1:4): R, = 0.28; HPLC: EtRet = 5.40. 10 Step 70.4: Trifluoro-methanesufonic acid 5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-Vl ester 1.324 mg (4.0 mmol) 6-hydroxy-naphthalene-1 -carboxylic acid (3-trifluoromethyl-phenyl)-amide are dissolved in 7.2 mL of pyridine and the solution collected to - 10 to -15 "C. Trifluorosulfonic acid anhydride (0.824 mL, 5 mmol) is added dropwise at that temperature over 10 minutes. 15 The mixture is then stirred at 0 0C for 10 minutes and then 2 h at rt. The reaction mixture is poured onto 25 mL of ice-H 2 0, stirred efficiently for a few minutes and then extracted with tert.-butyl-methylether. The organic phases are combined and washed with 1 N HCI and brine, dried with sodium sulfate and concentrated to about 15 to 20 mL. The suspension formed is cooled to 5 0C to complete he crystallization. The title compound is collected by 20 filtration and dried: m.p. 177-178 0C; MS: [M+1]*= 464; TLC (ethyl acetate/hexanes 3:7): Rf = 0.34; HPLC: Ett = 4.90. Example 71: 6-(6-Amino-pVrimidin-4-vlethynyl)-naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)-amide 25 In a three-necked flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer are placed 12.8 mL of dimethoxy-ethane and 2.2 mL of H 2 0. Nitrogen is bubbled through the solution for 5 minutes and then 33.3 mg (0.184 mmol) palladium chloride, 51.1 mg (0.263 mmol) copper (1) iodide and 191 mg (0.693 mmol) triphenylphosphine are added and the mixture is heated to 40 *C. Next, 6-trimethylsilanylethynyl-naphthalene-1 -carboxylic acid (3 30 trifluoromethyl-phenyl)-amide (0.412 g, 1 mmol), 4-amino-6-chloropyrimidine (165 mg, 1.25 mmol) and potassium carbonate (629 mg, 4.5 mmol) are added and the mixture stirred at 75 0C for 15 h. After cooling the organic layer is separated and treated with 2.5 g of silica gel. The solvent is removed and the crude product coated on silica gel chromatographed on a 40 g silica gel column on a Combi-Flash CompanionTm (Isco Inc.) apparatus using a gradient of 35 30% -+ 100% ethyl acetate in hexanes as solvent. The title compound is obtained as a tan solid: m.p. 217-220 0C; MS: [M+1]*= 433; TLC (ethyl acetate/hexanes 1:4): Rf = 0.19; HPLC: Eet = 3.36.
WO 2007/031265 PCT/EP2006/008857 49 Example 72: 6-(6-Amino-pvrimidin-4-vloxy)-1 H-indole-3-carboxylic acid (3-trifluoromethyl-phenyl) amide (Methode A). In a sealed tube, a solution of 50 mg (0.19 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 H-indole-3 5 carboxylic acid, 69.1 lI (0.56 mMol) 3-aminobenzotrifluoride and 128.9 lI (0.93 mMol) Et 3 N in 1 ml DMF was treated with 131 I (0.22 mMol) of propylphosphonic anhydride (ca. 50% in DMF) and stirred at RT overnight. The reaction mixture was directly purified by reversed phase prep-HPLC (Waters system) to give the title compound as its TFA salt: MS: [M+1]*= 414; HPLC: FtRt = 1.78. 10 The starting material is prepared as follows: Step 72.1: 6-Hydroxy-1 H-indole-3-carboxylic acid methyl ester. In a sealed flask, a mixture of 10.0 g (35.6 mMol) 6-benzyoxy-1 H-indole-3-carboxylic acid methyl ester (synthesized according to a literature procedure : M. Fedouloff and al. Bioorg. Med. 15 Chem. 9, 2001, 2119-2128), 2.26 g (35.6 mMol) ammonium formate and 3.78 g Pd/C 10% in 200 ml EtOH was stirred at RT for 1 h. The catalyst was filtered and washed with hot MeOH. The filtrate was evaporated to give the title compound: MS: [M+1 ]* = 192; HPLC: FtRet = 1.13. Step 72.2: 6-(6-Chloro-pyrimidin-4-yloxy)-1 H-indole-3-carboxylic acid methyl ester. 20 To a solution of 6.2 g (32.4 mMol) 6-hydroxy-1 H-indole-3-carboxylic acid methyl ester in 50 ml acetone, 35.7 ml (35.7 mMol) 1 N NaOH and 4.8 g (32.4 mMol) 4,6-dichloropyrimidine were added. The reaction mixture was stirred at RT for 1 h during which time the product precipitate. The reaction mixture was filtered and the solid washed with cold acetone/H 2 0 (1:1) then E20 to give the title compound which was used without further purification: MS: 25 [M+1 ]* = 304; H PLC: Ftet = 1.94. Step 72.3: 6-(6-Azido-pvrimidin-4-vloxy)-1 H-indole-3-carboxylic acid methyl ester. A mixture of 7.0 g (23.0 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-1 H-indole-3-carboxylic acid methyl ester and 3.0 g (46.1 mMol) NaN 3 in 75 ml DMF was stirred at 60*C for 2.5 h. The reaction 30 mixture was diluted in EtOAc then washed with H 2 0 and brine. The organic layer was dried over Na 2
SO
4 , filtered, and evaporated. Combi-Flash CompanionTM (Isco Inc.) column chromatography (SiO 2 ; gradient elution, hexane/EtOAc 8:2 -> 4:6) yielded the title compound: MS: [M+1]*= 311; HPLC: FtRe = 2.07. 35 Step 72.4: 6-(6-Amino-pyrimidin-4-vloxy)-1 H-indole-3-carboxylic acid methyl ester. In a sealed flask, a suspension of 3.4 g (11.0 mMol) 6-(6-azido-pyrimidin-4-yloxy)-1 H-indole-3 carboxylic acid methyl ester, 1.4 g (22.1 mMol) ammonium formate and 1.2 g Pd/C 10% in WO 2007/031265 PCT/EP2006/008857 50 65 ml EtOH was stirred at RT for 1 h. The catalyst was filtered through a Celite pad and washed with MeOH. The filtrate was evaporated to give the title compound which was used without further purification: MS: [M+1]*= 285; HPLC: FtRet = 1.08. 5 Step 72.5: 6-(6-Amino-pyrimidin-4-vloxy)-1 H-indole-3-carboxylic acid. A suspension of 3.38 g (11.9 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 H-indole-3-carboxylic acid methyl ester and 5.04 g (118.9 mMol) LiOH-H 2 0 in 136 ml MeOH / H 2 0 (5:3) was stirred at 80 0 C for 4 h. The clear solution was cooled to RT, acidified by the addition of 6.7 ml (178.0 mMol) formic acid, and concentrated under reduced pressure. The residue was diluted in 10 H 2 0 and the formed solid was filtered and washed with H 2 0 to yield the title compound: MS: [M+1]'= 271; HPLC: FtRet = 0.69. Example 73: 6-(6-Amino-pVrimidin-4-Vloxv)-1 H-indole-3-carboxylic acid (3-methoxy-phenyl)-amide (Methode B). 15 A solution of 50 mg (0.19 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 H-indole-3-carboxylic acid, 68.0 mg (0.56 mMol) 3-methoxyphenylamine, 102.0 LI (0.93 mMol) NMM and 106 mg (0.22 mMol) HATU in 1 ml DMF was stirred at RT overnight. The reaction mixture was directly purified by reversed phase prep-HPLC (Waters system) to give the title compound as its TFA salt: MS: [M+1 ]+ = 376; HPLC: Ftet 1.40. 20 Example 74: 6-(6-Amino-pyrimidin-4-vloxy)-1 H-indole-3-carboxylic acid (4-fluoro-3-trifluoromethyl phenyl)-amide (Methode C). A suspension of 50 mg (0.19 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 H-indole-3-carboxylic acid in 2 ml dioxane was treated with 134.6 L (1.85 mMol) SOC1 2 and stirred under reflux for 2 h. The 25 reaction mixture was evaporated under reduced pressure leading to the crude acid chloride. To a solution of the crude acid chloride in 2 ml NMP, 35.6 ol (0.278 mMol) 4-fluoro-3 (trifluoromethyl)aniline and 306 l (2.78 mMol) NMM were added. The reaction mixture was stirred at RT for 2 h then directly purified reversed phase prep-HPLC (Waters system). After lyophilization, the title compound was obtained as its TFA salt: MS: [M+1]*= 432; HPLC: GtRet 30 = 2.83. Example 75: The following compounds can be obtained analogously to Ex. 72, Ex. 73 or Ex. 74. H NO H
NH
2 OH
NH
2 N 0
R
WO 2007/031265 PCT/EP2006/008857 51 HPLC R Methode FtRe S [min] a) sA 1.61 380 H F b) F F A 1.76 414 H c) A 1.58 380 H d) N-N A 1.71 468 *N H e) -N B 1.40 364 H f) .sN B 1.48 360 H g) -N O1 B 1.33 376 H F F F h) C 2.21 490 H Example 76: 6-(6-Amino-pyrimidin-4-vloxy)-1 -methyl-1 H-indole-3-carboxylic acid (3-trifluoro methyl-phenyl)-amide. In a sealed flask, a solution of 16 mg (0.038 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-1 -methyl-1 H 5 indole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide in 1 ml NMP and 1 ml NH 4 0H 25% was stirred at 1200C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue purified by prep-HPLC to give the title compound as its TFA salt: MS: [M+1]* = 428; HPLC: FtRet = 1.87. 10 The starting material is prepared as follows: Step 76.1: 6-Benzyloxy-1 -methyl-1 H-indole-3-carboxylic acid methyl ester.
WO 2007/031265 PCT/EP2006/008857 52 To a solution of 2.33 g (8.28 mMol) 6-benzyloxy-1 H-indole-3-carboxylic acid methyl ester in 20 ml DMF, 4.05 g (12.42 mMol) Cs 2
CO
3 and 1.03 ml (16.57 mMol) Mel were added and the mixture was stirred at 600C for 3 h. The reaction middle was diluted in AcOEt and H 2 0, and the aqueous phase was extracted with AcOEt (3 times). The combined organic fractions 5 were washed with brine, then dried over Na 2
SO
4 , filtered, and evaporated. Purification via silica gel Combif lash chromatography (gradient elution, hexane / TBME 8:2 to 4:6) led to the title compound as a brownish solid: MS: [M+1]*= 296; HPLC: FtRej = 2.58. RF = 0.34 (TBME I hexane 1:1). 10 Step 76.2: 6-Benzyloxy-1 -methyl-1 H-indole-3-carboxylic acid. A suspension of 2.06 g (6.98 mMol) 6-benzyloxy-1 -methyl-1 H-indole-3-carboxylic acid methyl ester and 2.63 g (62.78 mMol) LiOH-H 2 0 in 75 ml MeOH / H 2 0 (2:1) was stirred at 60'C overnight. The clear solution was cooled to RT and concentrated. The residue was diluted in H20 and acidified by the addition of 2 M HCI. The formed white precipitate was collected by filtration, 15 washed with H 2 0 and dried at 40)C under high vacuum to give the title compound as an off white solid: MS: [M+1]* = 282; HPLC: FtRet = 2.12. Step 76.3: 6-Hydroxy-1 -methyl-1 H-indole-3-carboxylic acid. In a sealed flask, a suspension of 1.57 g (5.58 mMol) 6-benzyloxy-1 -methyl-1 H-indole-3-carboxylic 20 acid, 528 mg (8.37 mMol) ammonium formate and 594 mg Pd/C 10% in 25 ml EtOH was stirred at RT for 2 h. The catalyst was filtered and washed with hot MeOH. The filtrate was evaporated to give the title compound as an off-white solid: MS: [M+1 ]* = 192; HPLC: FtRet = 0.85. 25 Step 76.4: 6-(6-Chloro-pyrimidin-4-yloxy)-1 -methyl-1 H-indole-3-carboxylic acid. To a solution of 800 mg (4.18 mMol) 6-hydroxy-1 -methyl-1 H-indole-3-carboxylic acid in 20 ml acetone, 10 ml (10 mMol) 1 N NaOH and 935 mg (6.28 mMol) 4,6-dichloropyrimidine were added. The reaction mixture was stirred at RT for 2 h, then concentrated under reduced pressure. The residue was diluted in H 2 0 and extracted with CH 2
CI
2 (2 times). The aqueous 30 phase was acidified by the addition of 2 N HCI (-> pH 3-4) and the resulting slurry was extracted with AcOEt (3 times). The combined organic fractions were dried over Na 2
SO
4 , filtered and evaporated to yield the title compound as a brown solid which was used in the next step without further purification: MS: [M+1 ]*= 304; HPLC: FtRe = 1.68. 35 Step 76.5: 6-(6-Chloro-pyrimidin-4-vloxy)-1 -methyl-1 H-indole-3-carboxylic acid (3-trifluoro-methyl phenyl)-amide.
WO 2007/031265 PCT/EP2006/008857 53 A suspension of 60 mg (0.20 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-1 -methyl-1 H-indole-3-carboxylic acid in 2 ml dioxane was treated with 143.8 01 (1.98 mMol) SOCl 2 and stirred under ref lux for 2 h. The reaction mixture was evaporated under reduced pressure leading to the crude acid chloride. To the crude acid chloride in 2 ml NMP, 36.9 01(0.30 mMol) 3 5 (trifluoromethyl)aniline and 326.5 01(2.96 mMol) NMM were added. The reaction mixture was stirred at RT for 2 h then directly purified by injection in prep-HPLC (Waters system). After lyophilization, the title compound was obtained: MS: [M+1 ]* = 447; HPLC: FtRet = 2.76. Example 77: The following compounds can be obtained analogously to Ex. 76. N O0 N O0 J--H H Cl N NH2 O 10 HPLC MS R FtRet [M+1]+ [min] F a) - F1.90 446 H FF F F F F F 3.42 b) N (Gt) 504 H Example 78: 6-(6-Amino-pyrimidin-4-yloxy)-1 -ethyl-1 H-indole-3-carboxylic acid (3-trifluoromethyl phenyl)-amide. 15 Prepared as described in Ex. 74 from 50 mg (0.17 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 -ethyl 1 H-indole-3-carboxylic acid and 31.3 01 (0.25 mMol) 3-aminobenzotrifluoride: [M+1 ]* = 442; HPLC: FtRt = 1.93. The starting material is prepared as follows: 20 Step 78.1: 6-Benzyloxy-1 -ethyl-1 H-indole-3-carboxylic acid methyl ester. Prepared as described in Ex. 76, Step 76.1 from 2.0 g (7.11 mMol) 6-benzyloxy-1 H-indole-3 carboxylic acid methyl ester and 1.06 ml (14.22 mMol) ethyl bromide: [M+1]*= 310; HPLC: GtRet = 3.61.
WO 2007/031265 PCT/EP2006/008857 54 Step 78.2: 6-Benzyloxy-1 -ethyl-1 H-indole-3-carboxylic acid. Prepared as described in Ex. 76, Step 76.2 from 1.8 g (7.76 mMol) 6-benzyloxy-1 -ethyl-1 H-indole 3-carboxylic acid methyl ester: [M+1 ]* = 296; HPLC: FtRet 2.27. 5 Step 78.3: 6-Hydroxy-1 -ethyl-1 H-indole-3-carboxylic acid. Prepared as described in Ex. 76, Step 76.3 from 1.64 g (5.55 mMol) 6-benzyloxy-1 -ethyl-1 H indole-3-carboxylic acid: [M+1]*= 206; HPLC: FtRet 1.05. 10 Step 78.4: 6-(6-Chloro-pyrimidin-4-yloxy)-1-ethyl-1 H-indole-3-carboxylic acid. Prepared as described in Ex. 76, Step 76.4 from 1.21 g (6.33 mMol) 6-hydroxy-1 -ethyl-1 H-indole 3-carboxylic acid and 1.89 g (12.66 mMol) 4,6-dichloropyrimidine: [M+1 ]*= 318; HPLC: FtRet 1.85. 15 Step 78.5: 6-(6-Azido-pvrimidin-4-yloxy)-1 -ethyl-1 H-indole-3-carboxylic acid. A mixture of 1.5 g (4.72 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-1 -ethyl-1 H-indole-3-carboxylic acid and 1.23 g (18.88 mMol) NaN 3 in 15 ml DMF was stirred at 600C for 2.5 h. The reaction mixture was diluted in AcOEt then washed with 2 M HCI and brine. The organic layer was dried over Na 2
SO
4 , filtered, and evaporated. Combi-Flash CompanionTM (Isco Inc.) column 20 chromatography (Si02; hexane with 2% AcOH / EtOAc 8:2 -> 2:8) yielded the title compound: MS: [M+1 ]*= 325; HPLC: FtRet = 1.97. Ster, 78.6: 6-(6-Amino-pyrimidin-4-yloxy)-1 -ethyl-1 H-indole-3-carboxylic acid. Prepared as described in Ex. 72, Step 72.4 from 1.06 g (3.28 mMol) 6-(6-azido-pyrimidin-4-yloxy) 25 1-ethyl-1 H-indole-3-carboxylic acid, 418.0 mg (6.56 mMol) ammonium formate and 349.2 mg Pd/C 10%: [M+1]*= 299; HPLC: FtRet = 1.00. Example 79: 6-(6-Amino-pyrimidin-4-yloxy)-1 -ethyl-1 H-indole-3-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide. 30 Prepared as described in Ex. 78 from 50 mg (0.17 mMol) 6-(6-amino-pyrimidin-4-yloxy)-1 -ethyl 1H-indole-3-carboxylic acid and 32.3 01(0.25 mMol) 4-fluoro-3-(trifluoromethyl)aniline: [M+1]*= 460; HPLC: Ftet = 2.00. Example 80: 6-(6-Amino-pyrimidin-4-yloxy)-1 -iso-propyl-1 H-indole-3-carboxylic acid (3 35 trifluoromethyl-phenyl)-amide.
WO 2007/031265 PCT/EP2006/008857 55 Prepared as described in Ex. 76 from 18 mg (0.038 mMol) 6-(6-chloro-pyrimidin-4-yloxy)-1 -iso propyl-1H-indole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide: [M+1]*= 456; HPLC: GtRef = 3.14. 5 The starting material is prepared as follows: Step 80.1: 6-Benzvloxv-1-iso-propyl-1 H-indole-3-carboxylic acid methyl ester. Prepared as described in Ex. 76, Step 76.1 from 1.0 g (3.56 mMol) 6-benzyloxy-1H-indole-3 carboxylic acid methyl ester and 667 01 (7.10 mMol) 2-bromopropane: [M+1]*= 324; HPLC: GtRef = 3.72. 10 Step 80.2: 6-Benzyloxy-1 -iso-propyl-1 H-indole-3-carboxylic acid. Prepared as described in Ex. 76, Step 76.2 from 1.04 g (3.22 mMol) 6-benzyloxy-1-iso-propyl-1H indole-3-carboxylic acid methyl ester: [M+1]*= 310; HPLC: FtRet= 2.38. 15 Step 80.3: 6-Benzyloxy-1 -iso-propyl-1 H-indole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide. A suspension of 100 mg (0.32 mMol) 6-benzyloxy-1-iso-propyl-1H-indole-3-carboxylic acid in 2 ml dioxane was treated with 235.2 Al (3.23 mMol) SOC1 2 and stirred under reflux for 2 h. The reaction mixture was evaporated under reduced pressure leading to the crude acid chloride. To the crude acid chloride in 2 ml NMP, 60.3 D1(0.48 mMol) 3-(trifluoromethyl)aniline and 20 534.2 Dl (4.85 mMol) NMM were added. The reaction mixture was stirred at RT for 2 h then diluted in H 2 0 and extracted with TBME. The organic fraction was successively washed with 2 M HCI, 2 M Na 2
CO
3 , and brine, then dried over Na 2
SO
4 , filtered and evaporated. Combi Flash CompanionTM (Isco Inc.) column chromatography (SiO 2 ; hexane / EtOAc 95:5 -> 6:4) yielded the title compound: MS: [M+1 ]* = 453; HPLC: FtRet = 3.25. 25 Step 80.4: 6-Hydroxy-1 -iso-propyl-1 H-indole-3-carboxylic acid (3-trifluoromethyl-phenvl)-amide. Prepared as described in Ex. 76, Step 76.3 from 44 mg (0.097 mMol) 6-benzyloxy-1 -iso-propyl-1 H indole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide: [M+1 ]* = 363; HPLC: FtRet 2.43. 30 Step 80.5: 6-(6-Chloro-pyrimidin-4-vloxy)-1 -iso-propyl-1 H-indole-3-carboxylic acid (3 trifluoromethyl-phenyl)-amide. Prepared as described in Ex. 76, Step 76.4 from 34 mg (0.094 mMol) 6-hydroxy-1 -iso-propyl-1 H indole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide and 14.0 mg (0.094 mMol) 4,6 dichloropyrimidine: [M+1 ]* = 475; HPLC: FtRet = 3.00. 35 Example 81: 6-(6-Acetylaminopyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (4-piperazin-1 vlmethyl-3-trifluoromethylphenvl)amide WO 2007/031265 PCT/EP2006/008857 56 A solution of HCI (4.5 mL of 4M in dioxane) is added to a stirred solution of 6-(6-acetylamino pyrimidin-4-yloxy)-naphthalene-1-carbonylamino (2-trifluoromethyl-benzyl)-1-1 piperazinecarboxylic acid, 1,1 -dimethylethyl ester (step 81.3, 520 mg, 0.727 mmol) in dioxane (4.5 mL). After 2 hours, the mixture is neutralised with aqueous NaOH (2M). The 5 precipitated product is filtered, washed with H 2 0 and dried. The solid obtained s dissolved in
CH
2
CI
2 -MeOH (5:1) and the CH 2 Cl 2 is evaporated off under reduced pressure to afford a suspension which is filtered to give the title compound as a beige solid, m.p. 194-197 0 C. The starting material is prepared as follows: 10 Step 81.1: 6-(6-Chloropyrimidin-4-yloxy)-naphthalene-1 -carbonyl chloride A solution of oxalyl chloride (571 yL, 6.66 mmol) in CH 2 Cl 2 (15 mL) is added to an ice-cooled solution of 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Example 25, step 25.1; 1 g, 3.33 mmol) and DMF (10 pL) in CH 2 Cl 2 (30 mL). The reaction mixture is stirred at room temperature for 1 h. The solvent is then evaporated off under reduced pressure to 15 afford the title compound as a brown solid, which is used directly without further purification. Step 81.2: 6-(6-Chloropyrimidin-4-yloxy)-naphthalene-1-carbonylamino (2-trifluoromethyl-benzvl) 1 -piperazinecarboxylic acid, 1.1 -dimethylethyl ester A solution of 6-(6-chloropyrimidin-4-yloxy)-naphthalene-1-carbonyl chloride ( step 81. 1, 1.15 g, 20 2.89 mmol) in CH2Cl2 (20 mL) is added to a stirred solution of 4-(4-amino-2-trifluoromethyl benzyl)-1 -piperazinecarboxylic acid, 1,1 -dimethylethyl ester (922 mg, 2.51 mmol) and diisopropylethylamine (878 pL, 5.03 mmol) in CH 2 Cl 2 (20 mL). After 30 min, the reaction mixture is poured into a mixture of H 2 0 and CH 2 Cl 2 . The aqueous phase is separated off and extracted with CH 2
CI
2 . The combined organic layers are washed with H 2 0 and brine, dried 25 (Na 2
SO
4 ) and concentrated. Column chromatography (SiO 2 ; CH 2 Cl2 / EtOAc 1:1) gives the title compound as a brown solid. Step 81.3: 6-(6-Acetylamino-pyrimidin-4-vloxy)-naphthalene-1 -carbonylamino (2-trifluoromethyl benzvl)- -1 -piperazinecarboxylic acid, 1.1 -dimethylethyl ester 30 A mixture of 6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carbonylamino (2-trifluoromethyl benzyl)-1 -piperazinecarboxylic acid, 1,1 -dimethylethyl ester (step 81.2; 637 mg, 0.97 mmol), acetamide (86 mg, 1.46 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenylphosphine] (34 mg, 0.058 mmol), tris(dibenzylideneacetone)dipalladium (18 mg, 0.019 mmol), cesium carbonate (448 mg, 1.36 mmol) in dry dioxan (5 mL) is heated under an argon atmosphere at 35 70 0 C for 3 h. The cooled suspension is diluted with H 2 0, filtered (hyflo) and the residue is dissolved in EtOAc. The solvent is evaporated off under reduced pressure to afford the crude product which is used in the next step without further purification.
WO 2007/031265 PCT/EP2006/008857 57 Example 82: 6-(6-Amino-pyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (4-piperaz in-1 -ylmethyl-3-trifluoromethylphenyl)amide A solution of 6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid (4-piperazin-1 5 ylmethyl-3-trifluoromethylphenyl)amide (example 81 ; 260 mg, 0.39 mmol) in HCI (2 mL of 4M) - MeOH (2 mL) is heated at 50 0 C for 16 hours. After cooling, the solution is neutralised with NaOH (4 mL of 2M) and the resulting suspension is filtered and washed with H 2 0. The solid is then dried under high vacuum. Column chromatography (SiO 2 ; CH 2 Cl 2 / EtOH/ NH 3 90:9:1) gives the title compound as colourless solid: mp.: 123-128 0 C. 10 Example 83: 6-(5-(4-Piperazin-1-ylmethyl-3-trifluoromethVlphenvlcarbamoyl)naphthalene-2 VloxV)pyrimidin-4-Vl)carbamic acid methyl ester This compound can be obtained analogously to example 81, utilising methylcarbamate in lieu of acetamide in the step 81.3. Beige solid, m.p. 138-148*C. 15 Example 84: 6-(6-Acetylamino-pyrimidin-4-vloxy)-naphthalene-1-carboxylic acid (4-(4-methyl piperazin-1 -vlmethyl-3-trifluoromethylphenvl)amide This compound can be obtained analogously to example 81, utilising 4(-4-methylpiperazin-1 ylmethyl)-3-trifluoromethylphenylamine in lieu of 4-(4-amino-2-trifluoromethylbenzyl)-1 20 piperazinecarboxylic acid, 1,1 -dimethylethyl ester in the step 81.2. Beige powder, 1 H NMR (400 MHz, DMSO-D6) 5 ppm 2.11 (3 H, s) 2.15 (3H, s) 2.26-2.44 (8 H, m) 3.57 (2 H, s) 7.45 (1 H, dd, J=9.2, 2.4 Hz) 7.61 (1 H, s) 7.64 (1 H, dd, J-8.0, 7.2 Hz) 7.70 (1 H, d, J=8.6 Hz) 7.78 (1 H, dJ=7.0 Hz) 7.85 (1 H, d, J=2.4 Hz) 7.99 (1 H, d, J=8.8 Hz) 8.07 (1 H, d, J-8.5 Hz) 8.25 (1 H, s) 8.25 (1 H, dd, J=5.1, 4.1 Hz) 8.48 (1 H, s) 10.86 (1 H, s) 10.96 (1 H, s). 25 Example 85: 6-(6-Aminopyrimidin-4-vloxy)-naphthalene-1-carboxylic acid (4-(4-methyl-piperazin 1 -vlmethyl-3-trifluoromethyl-phenyl)-amide This compound can be obtained analogously to example 82, utilising 6-(6-acetylamino-pyrimidin-4 yloxy)-naphthalene-1-carboxylic acid (4-(4-methyl-piperazin-1-ylmethyl-3 30 trifluoromethylphenyl)amide (example 4) in lieu of 6-(6-Acetylamino-pyrimidin-4 yloxy)naphthalene-1 -carboxylic acid (4-piperazin-1 -ylmethyl-3-trifluoromethylphenyl)amide. Colourless powder, 1H NMR (400 MHz, DMSO-D6) 8 ppm 2.15 (3 H, s) 2.29 - 2.35 (4 H, m) 2.36 - 2.43 (4 H, m) 3.57 (2 H, s) 5.79 (1 H, d, J=1.0 Hz) 6.86 (2 H, s) 7.39 (1 H, dd, J=9.2, 2.5 Hz) 7.62 (1 H, dd, J=8.1, 7.1 Hz) 7.70 (1 H, d, J=8.3 Hz) 7.76 (1 H, dd, J=7.3, 1.3 Hz) 35 7.77 (1 H, d, J=2.5 Hz) 7.99 (1 H, dd, J=8.6, 1.2 Hz) 8.06 (1 H, d, J=8.1 Hz) 8.06 (1 H, d, J=1.0 Hz) 8.23 (1 H, d, J=8.1 Hz) 8.24 (1 H, s) 10.83 (1 H, s) WO 2007/031265 PCT/EP2006/008857 58 Example 86: 6-(5-(4-(4-methylpiperazin-1 -vlmethyl-3-trifluoromethvlphenvlcarbamovl) naphthalene-2-vloxv)pvrimidin-4-vl)carbamic acid methyl ester This compound can be obtained analogously to example 81, utilising 4(-4-methylpiperazin-1 ylmethyl)-3-trifluoromethyl-phenylamine in lieu of 4-(4-amino-2-trifluoromethyl-benzyl)-1 5 piperazinecarboxylic acid, 1,1 -dimethylethyl ester in the step 81.2. and employing methylcarbamate in lieu of acetamide in the step 81.3. Colourless powder, 1 H NMR (400 MHz, DMSO-D6) 8 ppm 2.15 (3 H, s) 2.24 - 2.47 (8 H, m) 3.57 (2 H, s) 3.68 (3 H, s) 7.38 (1 H,s) 7.47 (1 H, dd, J=9.2, 2.3 Hz,) 7.66 (1H, dd, J=8.2, 7.3 Hz) 7.72 (1 H, d, J=8.6 Hz) 7.80 (1 H, d, J=7.0 Hz) 7.88 (1 H, d, J=2.3 Hz) 8.01 (1 H, d, J=8.21 Hz) 8.09 (1 H, d, J=8.2 Hz) 10 8.22 - 8.31 (m,2 H) 8.46 (1 H, s) 10.86 (1 H, s) 10.90 (1 H, s) Example 87: 6-(6-Acetylamino-pyrimidin-4-yloxy)naphthalene-1 -carboxylic acid (4-(4 isopropylpiperazin-1-vlmethyl-3-trifluoromethylphenyl)amide This compound can be obtained analogously to example 81, utilising 4(-4-isopropylpiperazin-1 15 ylmethyl)-3-trifluoromethylphenylamine in lieu of 4-(4-amino-2-trifluoromethyl-benzyl)- 1 piperazinecarboxylic acid, 1,1 -dimethylethyl ester in step 81.2. pale yellow crystalline solid, m.p. = 210-213*C. Example 88: 6-(6-Aminopyrimidin-4-vloxy)-naphthalene-1 -carboxylic acid (4-(4-isopropyl 20 piperazin-1 -ylmethyl-3-trifluoromethylphenyl)amide This compound can be obtained analogously to example 82, utilising 6-(6-acetylaminopyrimidin-4 yloxy)-naphthalene-1 -carboxylic acid (4-(4-isopropylpiperazin-1 -ylmethyl-3 trifluoromethylphenyl)amide (example 87) in lieu of 6-(6-Acetylamino-pyrimidin-4-yloxy) naphthalene-1-carboxylic acid (4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide. 25 Colourless powder, m.p. 185-189 0 C. Example 89: 6-(5-(44-sopropylpiperazin-1 -ylmethyl-3-trifluoromethyl-phenylcarbamoyl) naphthalene-2-vloxy)-pyrimidin-4-yl)carbamic acid methyl ester This compound can be obtained analogously to example 81, utilising 4-(4-isopropylpiperazin-1 30 ylmethyl)-3-trifluoromethylphenylamine in lieu of 4-(4-amino-2-trifluoromethylbenzyl)-1 piperazinecarboxylic acid, 1,1 -dimethylethyl ester in step 81.2. and employing methylcarbamate in lieu of acetamide in the step 81.3. Colourless powder, m.p. = 175-178*C. Example 90: 7-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid [4-(4-methyl 35 piperazin-1 -vlmethyl)-3-trifluoromethyl-phenyll-amide A mixture of 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid [4-(4-methyl-piperazin-1 ylmethyl)-3-trifluoromethyl-phenyl]-amide WO 2007/031265 PCT/EP2006/008857 59 (step 90.1; 300 mg, 0.54 mmol), acetamide (47.7 mg, 0.81 mmol), (9,9-dimethyl-9H-xanthene-4,5 diyl)bis[diphenylphosphine] (18.7 mg, 0.032 mmol), tris(dibenzylideneacetone)dipalladium (10 mg, 0.0108 mmol), cesium carbonate (248 mg, 0.75 mmol) in dry dioxan (3 mL) is heated under an argon atmosphere at 70 0 C for 3 h. The cooled suspension is diluted with H 2 0, 5 filtered (hyflo) and the residue is dissolved in EtOAc. The solvent is evaporated off under reduced pressure to afford the crude product which is chromatographed by reversed phase MPLC (Bichi system), yielding, after neutralisation with saturated aqueous NaHCO 3 , the title compound as a beige solid, 1H NMR (400 MHz, DMSO-D6) Olppm 2.13 (3 H, s) 2.15 (3 H, s) 2.33 (4 H, s) 2.36 - 2.42 (4 H, m) 3.43 (1 H, ddd, J=1 3.93, 6.98, 5.05 Hz) 3.57 (2 H, s) 7.67 (1 10 H, d, J=0.76 Hz) 7.72 (1 H, d, J=9.16 Hz) 7.75 (1 H, dd, J=9.09, 2.27 Hz) 7.99 (1 H, dd, J=8.21, 1.52 Hz) 8.08 (1 H, d, J=2.46 Hz) 8.24 (1 H, d, J=1.71 Hz) 8.33 (1 H, d, J=9.16 Hz) 8.49 (2 H, d, J=0.82 Hz) 8.80 (1 H, s) 9.43 (1 H, s) 10.99 (1 H, s) 11.00 (1 H, s). The starting material is prepared as follows: 15 Step 90.1: 7-(6-Chloro-pyrimidin-4-vloxy)-isoquinoline-4-carboxylic acid [4-(4-methyl-piperazin-1 vlmethvl)-3-trifluoromethyl-phenyll-amide A mixture of 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid (1.95 g, 5.5 mmol), 4-(4 Methyl-piperazin-1 -ylmethyl)-3-trifluoromethyl-phenylamine (1.5 g, 5.49 mmol) and triethylamine (6.42 mL, 46.2 mMol) in dry DMF (50 mL) is heated under an argon 20 atmosphere at 50 0 C. A solution of propylphosphonic anhydride (5.4 mL, 8.2 mmol) 50% in DMF is then added. After 2 h, the reaction mixture is poured onto an aqueous solution of NaHCO 3 and stirred at 0*C for 1 h. The suspension is then filtered (hyf lo) and the solid residue is dissolved in CH 2
C
2 - MeOH (5:1). The solvent is evaporated off under reduced pressure to afford a crude product which is purified by reversed phase MPLC (B~chi system), 25 yielding, after neutralisation with saturated aqueous NaHCO 3 , the title compound as a orange solid. Example 91: (6-{4-[4-(4-Methyl-piperazin-1-vlmethyl)-3-trifluoromethyl-phenvlcarbamoyll isoquinolin-7-vloxyl-pyrimidin-4-vl)-carbamic acid methyl ester 30 This compound can be obtained analogously to example 90, utilising methylcarbamate in lieu of acetamide. Beige solid, 1H NMR (400 MHz, DMSO-D6) 8 ppm 2.15 (3 H, s) 2.29 - 2.35 (4 H, m) 2.36 - 2.43 (4 H, m) 3.57 (2 H, s) 3.69 (3 H, s) 7.43 (1 H, d, J=1.0 Hz) 7.72 (1 H, d, J=8.5 Hz) 7.75 (1 H, dd, J=9.1, 2.4 Hz) 7.99 (1 H, dd, J=8.6, 1.1 Hz) 8.09 (1 H, d, J=2.5 Hz) 8.24 (1 H, d, J=2.1 Hz) 8.34 (1 H, d, J=9.2 Hz) 8.45 (1 H, d, J=1 Hz) 8.80 (1 H, s) 9.43 (1 H, d, J=0.5 35 Hz) 10.86 (1 H, s) 10.99 (1 H, s). Example 92: Via analogous routes the following derivative can be obtained WO 2007/031265 PCT/EP2006/008857 60 N N O N N N, 5 NH2 O NN F H IF F Example 93: 7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid [5-tert-butyl-2-(4 10 isopropyl-phenyl)-2H-pyrazol-3-yil-amide 7-(6-Azido-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid [5-tert-butyl -2-(4-isopropyl-phenyl) 2H-pyrazol-3-yl]-amide (49.0 mg, 0.089 Mmol) is dissolved in MeOH (5 ml) and submitted to hydrogenation over Raney-Nickel (12 mg) at atmospheric pressure at rt for 4 h. After completion the reaction mixture is filtered over a pad of celite and concentrated to give the 15 title compound. MS: [M+1]*= 522. Mp 131-133 *C. The starting material is prepared as follows: Step 93.1: 7-Hydroxy-isoquinoline-4-carboxylic acid 7-Methoxy-isoquinoline-4-carboxylic acid (2.5 g, 12.3 mMol) is dissolved in HBr/HOAc (33% wt; 10 20 mL) and H20 (0.5 mL) is added. The reaction mixture is warmed to 130 *C in a sealed tube. After 3 h it is allowed to cool to ambient temperature. All volatiles are removed under reduced pressure and the remaining crude product is used without further purif ication for the next step. 25 Step 93.2: 7-(6-Chloro-pyvrimidine-4-yloxy)-isoquinoline-4-carboxylic acid 7-Hydroxy-isoquinoline-4-carboxylic acid (2.3 g, 12.3 Mmol) is dissolved acetone (60 mL) and an aqueous solution of NaOH (1 M, 27 mL) is added, followed by 4,6-dicloropyrimidine (1.9 g, 13.2 mMol). The reaction is stirred at ambient temperature for 12h and acetone is removed under reduced pressure. The remaining aqueous solution is acidified with aqueous HCl (1 30 M). The resulting yellow precipitate of the product is isolated by filtration, washed repeatedly with cold H20 and dried under high vacuum at 60"C. Step 93.3: 7-(6-Chloro-pyvrimidine-4-yloxy)-isoquinoline-4-carboxyl choride 7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid (1.6 g, 5.5 Mmol) is suspended in 35 CH2Cl2 and oxalylchloride (0.57 mL, 6.6 Mmol ) is added. The reaction is then stirred under reflux for 2 h , cooled to ambient temperature and concentrated under reduced pressure. The remaining crude product is used without further purification for the next step.
WO 2007/031265 PCT/EP2006/008857 61 Step 93.4: 7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid [5-tert-butyl -2-(4 isopropyl-phenvl)-2H-pyrazol-3-vil-amide 7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxyl choride (0.5 g, 1.5 Mmol) is dissolved -in 5 CH 2 Cl 2 (4 mL) and a solution of 5-tert-butyl-2-(4-isopropyl-phenyl)-2-H-pyrazol-3-ylamine (described for example in GB 0500435.3; 0.4 g, 1.5 Mmol) and pyridine (76 OL, 1.7 Mmol) dissolved in CH 2 Cl 2 (4 mL) is added dropwise at rt. The reaction is stirred for 1.5 h at rt and then concentrated under reduced pressure. The residual crude product is purified by flash chromatography (SiO 2 , CH 2
CI
2 /MeOH, gradient 0-8 % MeOH) to give the title compound as a 10 yellow solid. Step 93.5: 7-(6-Azido-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid [5-tert-butyl -2-(4 isopropVl-phenVl)-2H-pyrazol-3-Vll-amide 7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid [5-tert-butyl -2-(4-isopropyl-phenyl) 15 2H-pyrazol-3-yl]-amide (128.0 mg, 0.24 Mmol) is dissolved in DMF (5 mL) and NaN 3 (31.0 mg, 0.47 Mmol) is added in one portion at it. The reaction mixture is stirred for 1.5 h at 700C and then concentrated under reduced pressure. The residual crude product is submitted to flash chromatography (SiO 2 ; CH 2
CI
2 /MeOH; gradient 0-5 % MeOH) to give the title compound as a yellow solid. 20 Example 94: 7-(6-Amino-pyrimidin-4-vloxy)-isoquinotine-4-carboxylic acid [5-tert-butyl-2-(4-fluoro vhenyl)-2H-pyrazol-3-yll-amide The title compound is prepared in analogy to Ex. 93 using 5-tert-butyl-2-(4-fluoro-phenyl)-2H pyrazol-3-ylamine . MS: [M+1]*= 498. Mp 124-126 C. 25 Example 95: 7-(6-Methylamino-p~vrimidin-4-vloxy)-isoquinoline-4-carboxylic acid (4-fluoro-3 trifluoromethyl-phenyl)-amide 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl) amide (490 mg, 1.0 Mmol) is treat with a solution of methylamine in EtOH (33% wt) at rt. The 30 reaction mixture is stirred for 1.5 h at ambient temperture. It is then concentrated under reduced pressure and the remaining crude product submitted to flash chromatography (SiO 2 ,
CH
2
CI
2 /MeOH; gradient 1-8 % MeOH) to give the title compound as a yellow solid. MS: [M+1 ]' = 458. Mp 255-257 *C. 35 The starting material is prepared as follows: Step 95.1: 7-(6-Chloro-pyrimidin-4-vloxy)-isoquinoline-4-carboxylic acid (4-fluoro-3-trifluoromethyl phenyl)-amide WO 2007/031265 PCT/EP2006/008857 62 The title compound is prepared in analogy to Step 93.4. from 7-(6-Chloro-pyrimidine-4-yloxy) isoquinoline-4-carboxyl choride and 4-f luoro-3-trif lourometyl-phenylamine. Example 96:7-(6-Methylamino-pyrimidin-4-vloxy)-isoquinoline-4-carboxylic acid (3-trifluoromethyl 5 phenyl)-amide The title compound is prepared in analogy to Ex. 95 from 3-trifluoromethyl-phenylamine. MS: [M+1]*= 440. Mp 205-208 0C. Example 97: The following compounds can be obtained in analogy to Example 93 (Q = H) or 10 Example 95 (1 4 = CH 3 ) starting from 6-(6-chloropyrimidin-4-yloxy)-naphthalene-1 -carbonyl chloride (step 81.1) and appropriate 2-amino pyrazoles (described for example in GB 0500435.3). MS [M+1]+ Mpf1c] Name a) 550 130-135 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid 5-tert-butyl-2-(4 dimethylaminomethyl-phenyl)-2H-pyrazole-3-yl amide b) 605 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene- carboxylic acid {5-tert-butyl-2-4-(4-methyl-piperazin 1 -ylmethyl)-phenyl)-2H-pyrazol-3-yl}-amide c) 578 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid [5-tert-butyl-2-4-(4-morpholin-4-ylmethyl) phenyl)-2H-pyrazol-3-yiI-amide d) 592 125-128 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid [5-tert-butyl-2-4-(4-morpholin-4 ylmethyl)-phenyl)-2H-pyrazol-3-yl]-amide e) 507 105-110 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid [5-tert-butyl-2-4-(3-methyl-phenyl) 2H-pyrazol-3-yi]-amide f) 592 105-1 10 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid [5-tert-butyl-2-4-(4-morpholin-3 ylmethyl)-phenyl)-2H-pyrazol-3-yl]-amide g) 536 140-145 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid [5-tert-butyl-2-(3-dimethylaminometylphenyl) 2H-pyrazol-3-yi]-amide h) 550 114-116 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 - WO 2007/031265 PCT/EP2006/008857 63 MS [M+1]+ MP[*C Name carboxylic acid [5-tert-butyl-2-(3 dimethylaminometylphenyl)-2H-pyrazol-3-y]-amide i) 550 290-291 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1 -carboxylic acid [5-tert-butyl-2-(3-dimethylcarbamoyl-phenyl) 2H-pyrazol-3-yl]-amide ) 564 247-249 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1 carboxylic acid [5-tert-butyl-2-(3-dimethylcarbamoyl phenyl)-2H-pyrazol-3-yli]-amide Example 98: Dry-filled capsules 5000 capsules, each comprising as active ingredient 0.25 g of one of the compounds of formula I mentioned in the preceding Examples, are prepared as follows: 5 Composition active ingredient 1250 g talcum 180 g wheat starch 120 g 10 magnesium stearate 80 g lactose 20 g Preparation process: The mentioned substances are pulverised and forced through a sieve of 0.6 mm mesh size. 0.33 g portions of the mixture are introduced into gelatin capsules using a 15 capsule-filling machine. Example 99: Soft capsules 5000 soft gelatin capsules, each comprising as active ingredient 0.05 g of one of the compounds of formula I mentioned in the preceding Examples, are prepared as follows: 20 Composition active ingredient 250 g PEG 400 1 litre Tween 80 1 litre 25 Preparation process: The active ingredient is pulverised and suspended in PEG 400 (polyethylene glycol having an M, of from approx. 380 to approx. 420, Fluka, Switzerland) and Tween*80 (polyoxyethylene sorbitan monolaurate, Atlas Chem. Ind. Inc., USA, supplied by Fluka, WO 2007/031265 PCT/EP2006/008857 64 Switzerland) and ground in a wet pulveriser to a particle size of approx. from 1 to 3 pm. 0.43 g portions of the mixture are then introduced into soft gelatin capsules using a capsule-filling machine. 5 Example 100: Inhibition of the tyrosine kinase activity of VEGF-R2 (KDR) The inhibition test is carried out as described above. The ICso values for some of the compounds of formula I are given below: Compound from KDR Example No. ICSO [PM] 8 0.046 9 0.029 10 0.037 12a) 0.052 12b) 0.010 12d) 0.073 12f) 0.017 15 0.020 17a) 0.019 17b) 0.054 17c) 0.018 18 0.021 20 0.024 21 0.019 22 0.096 25 0.036 26a) 0.021 Example 101: Penetration / Permeation Studies 10 a) Skin donors and preparation Frozen human dorsal cadaver skin (Caucasian; back skin) was obtained from the National Disease Research Interchange, Philadelphia, USA. Skin from three different donors was used; Thawed skin samples were dermatomed to 0.7 mm with an Aesculap dermatome to obtain "split thickness" skin. 15 b) Penetration assay Percutaneous penetration was studied in vitro by means of static Franz-type diffusion cells with phosphate buffered saline/ fetal calf serum 2:1 as receptor fluid at 320 in triplicates for 48 hours. The compounds were applied as 1 % solutions (300 pl each) in propylene glycol (solution a) or in propylene glycol / oleyl alcohol 9:1 (solution b). Samples of 100 pl were taken 5 to 7 times and 20 replaced by fresh receptor fluid as described previously (Schmook, et al., Skin Pharmacol. 1993, 6:116-124).
WO 2007/031265 PCT/EP2006/008857 65 c) Sample processing Drug analysis was performed with specimens of the exposed skin (at the end of the 48 hours experiment), from which the stratum corneum had been removed by 20 strippings with an adhesive tape. The weighed skin samples were homogenized in 0.2 M ammonium phosphate buffer (pH 5 7.0). The homogenates were extracted with ethyl acetate and processed as described (Schmook, et al 1993). Skin concentrations as a measurement for skin penetration for different compounds as given in the examples were found to be enhanced by a factor 5 to 500, e.g. 10 to 100, when given as solutions 10 b as compared to those values when given as solutions a. Some specific values for the compounds given and applied as solutions b are given in TABLE 1 and in TABLE 2 and applied as solutions a, c and d are given in TABLE 3. When these compounds were applied as solutions a) at least 10-fold lower skin concentrations and quasi undetectable (negligible) skin permeation was found. 15 TABLE 1: Compound Batch of Skin Permeation rate skin concentration [ng/ml/hr} [pg/g] N N2 44 ±17 13±3
NH
2 F H F 3 24±68 2 F N 0 3 34 3 12 4
NH
2 F H F F N 0 N F 3 19 7 22±3
NH
2 O 0 N F H F
F
WO 2007/031265 PCT/EP2006/008857 66 N N N 3 46 13 19±3 NH2 0 NH F F F F TABLE 2: Compound Batch of Skin concentration Permeation rate skin [pg/gI [ng/ml/hr] 1 35 ±12 182 ±68 21 N '\ / N 2 72 ±24 189 ±43 N NN1 10.4±2.0 286 90 5 Table 3 shows corresponding specific using the skin model as described before of a compound of formula lp CINRPorbDCC\RBRuIum70f_1 DOC-9/116/2011M 67 Ni 'Y'
NH
2 F 0 N H F F When applied as a solution in propylene glycol (= solution a) or in propylene glycol containing 0.1% DMSO (= solution c), or as a solution of propylene glycol containing 1 % DMSO (= solution d) 5 equally low skin concentrations and quasi undetectable (negligible) permeation were found. TABLE 3: Skin Permeation rate Formulation of compound of formula lp as Batch of skin concentration [ng/ml/hr] [pg/g] solution a 4 4.2 ±1.5 <2 solution b 4 4.4 ± 3.1 <2 solution c 4 4.7 ± 2.9 <2 10 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. 15 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (14)

1. A composition comprising a VEGF receptor inhibitor and a penetration enhancer, wherein the VEGF receptor inhibitor is a compound of formula A Y G O N XB ENW (I) Z N R2 H 5 R wherein R 1 is H, halo; -(CO. 7 )-R 3 , -(CO_ 7 )-NR 4 R 5 , or -C(=O)-R 6 : R 2 is substituted (C 3 .)cycloalkyl; substituted aryl; or substituted heterocyclyl; R 3 is H or unsubstituted or substituted (C 1 . 4 )alkyl; 10 R 4 and R 5 are independently selected from the group consisting of H; unsubstituted or substituted (C14) alkyl; (C 1 . 4 )alkyl-carbonyl, wherein the (C.4)alkyl moiety is optionally substituted; and (C. 4 )alkoxy-carbonyl, wherein the (C 1 .4)alkyl moiety is optionally substituted; R6 is H; unsubstituted or substituted (C1.4) alkyl; (C 1 . 4 )alkoxy, wherein the (C 1 4)alkyl moiety 15 is optionally substituted; or unsubstituted, mono- or di-substituted amino; A, B and X are independently selected from =C(R 7 )- or N; E, G and T are independently selected from =C(R 8 )- or N; R 7 and R 8 are independently selected from the group consisting of H, halo and unsubstituted or substituted (C 1 . 4 )alkyl; 20 Y is -0-, -S-, -S(0)-, -S(O) 2 -, -CH 2 - or -CH
2 -CH 2 -, Z is CH or N and Q is (C 14 )alkylene or (C 2 .4)alkylene, wherein (C 1 a)alkylene or (C2. 4 )alkenylene optionally may be substituted and wherein one or more of the carbon atoms of said (C 1 4)alkylene or (C 2 - 4 )alkenylene chain optionally may be replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur; and the bond between 0 and Z 25 characterized by a dotted line is a single bond; with the proviso that if Z is N, Q is not unsubstituted unbranched (C 14 )alkylene; or Z is C and Q is as defined above wherein the bond between Q and Z characterized by a dotted line is a double bond; and W is either not present or (C1-3)alkylene; 30 or a tautomer thereof, or in the form of a salt, a solvate or in the form of a salt and a solvate, and wherein the penetration enhancer is selected from the group consisting of unsaturated fatty acids, unsaturated fatty acid esters and unsaturated fatty acid alcohols. 35 2. A composition of claim 1, wherein the VEGF receptor inhibitor is a compound of formula (1), wherein C WRPonbl\DCCRR3f xN)06_ 1 DOC-lh/06/2010 69 R 1 is halo; -(C 07 )-NR 4 R 5 ; or -C(=O)-R 6 ; R 2 is substituted (C 3 .B)cycloalkyl; substituted aryl; or substituted heterocyclyl; R 4 and R 5 are independently selected from the group consisting of H; (C 1 . 4 )alkyl; (C 1 . 4 )alkyl - carbonyl; and (Cl. 4 )alkoxy-carbonyl; 5 R 6 is (C 1 4 )alkyl, (C 1 4 )alkoxy, (C 1 . 4 )alkyl-amino, di-(Cl. 4 )alkyl-amino-(C.4)alkyl-amino or di (C1.4)alkyl-amino; A, B and X are independently selected from =C(R 7 )- or N, E, G and T are =C(RB)-; R 7 and R 8 are independently selected from H and halo; 10 Y is -0-, -S- or -CH 2 -, especially -0 Z is N and 0 is (Cl. 4 )alkylene or (C 2 . 4 )alkenylene, wherein one or more, especially one, of the carbon atoms of said (Cl.a)alkylene or (C 2 . 4 )alkenylene chain optionally may be replaced by a heteroatom independently selected from N, 0 and S, especially from 0, the N optionally substituted by (C 14 )alkyl; and the bond between Q and Z characterized by a 15 dotted line in formula I is a single bond; with the proviso that Q is not unsubstituted unbranched (C 1 4 )alkylene; or Z is C and Q is as defined above wherein the bond between Q and Z characterized by a dotted line in formula I is a double bond; and 20 W is (C1-3)alkylene or especially not present.
3. A composition of claim 1 or 2, wherein the VEGF receptor inhibitor is a compound of formula (1), wherein Z is N and Q is (C 2 . 4 )alkenylene, or (C 1 .4)alkylene wherein one or more, especially one, of 25 the carbon atoms of (Cl 4 )alkylene is replaced by a heteroatom independently selected from N, 0 and S, especially from 0; and the bond between Q and Z characterized by a dotted line in formula I is a single bond; or Z is C and Q is as defined above wherein the bond between Q and Z characterized by a dotted line in formula I is a double bond. 30
4. A composition of any one of claims 1 to 3, wherein the VEGF receptor inhibitor is a compound of formula (1), wherein Ais N and B is=CHor Bis N and Ais=CH, X is =CH, 35 Y is 0. E, G and T are =CH, Z is C. Q is -CH=CH-CH=, W is not present, C-\NRPonbl\DCC\RBRk )9i-I DOC- 1/1)7121111 70 R, is -(Co. 7 )-NR 4 R 5 and R 4 and R 5 are as defined above, R 2 is substituted aryl.
5. A composition of any one of claims 1 to 4, wherein the VEGF receptor inhibitor is a 5 compound of formula N N -- NH 2 F 0 N H F F or a pharmaceutically acceptable salt thereof.
6. A composition of any one of claims 1 to 5 in the form of a cream. 10
7. A composition of any one of claims 1 to 5 for use as a topical pharmaceutical.
8. A composition of any one of claims 1 to 5 for the manufacture of a medicament. 15
9. Use of a composition of any one of claims 1 to 5 for the manufacture of a medicament for the treatment of a dermatological disease selected from the group consisting of psoriasis, atopic dermatitis and acne.
10. A pharmaceutical composition comprising a composition of any one of claims 1 to 5 in 20 association with at least one pharmaceutical excipient.
11. A pharmaceutical composition of claim 10, further comprising another pharmaceutically active agent. 25
12. A method of treatment of a dermatological disease selected from the group consisting of psoriasis, atopic dermatitis and acne, which treatment comprises administering to a subject in need of such treatment an effective amount of a composition of any one of claims 1 to 5.
13. A method of claim 13, wherein a composition of any one of claims 1 to 5 is administered in 30 combination with another pharmaceutically active agent, either simultaneously or in sequence.
14. A composition according to ciaim 1 or a use according to claim 9 or a method accoidiny to claim 12 substantially as hereinbefore described and/or exemplified. 35
AU2006291526A 2005-09-13 2006-09-12 Combinations comprising a VEGF receptor inhibitor and a penetration enhancer Ceased AU2006291526B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0518672.1 2005-09-13
GB0518671.3 2005-09-13
GB0518671A GB0518671D0 (en) 2005-09-13 2005-09-13 Organic compounds
GB0518672A GB0518672D0 (en) 2005-09-13 2005-09-13 Organic compounds
PCT/EP2006/008857 WO2007031265A2 (en) 2005-09-13 2006-09-12 Combinations comprising a vegf receptor inhibitor and a penetration enhancer

Publications (2)

Publication Number Publication Date
AU2006291526A1 AU2006291526A1 (en) 2007-03-22
AU2006291526B2 true AU2006291526B2 (en) 2010-07-29

Family

ID=37663150

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006291526A Ceased AU2006291526B2 (en) 2005-09-13 2006-09-12 Combinations comprising a VEGF receptor inhibitor and a penetration enhancer

Country Status (23)

Country Link
US (2) US20080306058A1 (en)
EP (1) EP1945217B1 (en)
JP (1) JP2009507871A (en)
KR (1) KR20080058376A (en)
AR (1) AR056194A1 (en)
AT (1) ATE555790T1 (en)
AU (1) AU2006291526B2 (en)
BR (1) BRPI0615881A2 (en)
CA (1) CA2621399A1 (en)
EC (1) ECSP088259A (en)
GT (1) GT200600411A (en)
IL (1) IL189984A0 (en)
MA (1) MA29788B1 (en)
MY (1) MY145751A (en)
NO (1) NO20081807L (en)
NZ (1) NZ566474A (en)
PE (1) PE20070457A1 (en)
RU (1) RU2424804C2 (en)
SA (1) SA06270315B1 (en)
SG (1) SG165371A1 (en)
TN (1) TNSN08112A1 (en)
TW (1) TWI325321B (en)
WO (1) WO2007031265A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
MX2009011207A (en) 2007-04-17 2009-12-07 Novartis Ag Ethers of naphtalene carboxylic acid amides as cancer cure.
WO2009026408A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
JO3265B1 (en) 2008-12-09 2018-09-16 Novartis Ag Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
JP2014505052A (en) * 2011-01-06 2014-02-27 ベータ ファルマ カナダ インコーポレーテッド New urea for cancer treatment and prevention
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CA2857156C (en) * 2011-12-01 2019-09-24 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CN107245071A (en) * 2013-04-09 2017-10-13 广州慧柏瑞生物医药科技有限公司 The compound of anti-new vessels, its intermediate and application thereof
WO2015064764A1 (en) * 2013-11-01 2015-05-07 宇部興産株式会社 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof
JP6879740B2 (en) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド How to Treat Lymphatic Plasma Cell Lymphoma
CN104860885B (en) 2014-02-24 2017-11-17 中国科学院上海药物研究所 Naphthoyl aminated compounds, preparation method and use
JO3705B1 (en) * 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
CN107098884A (en) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 The aminopyridines and its preparation and use of one class substitution
RU2743170C2 (en) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Substituted indazoles suitable for treating and preventing allergic and/or inflammatory diseases in animals
WO2021170078A1 (en) * 2020-02-28 2021-09-02 上海润石医药科技有限公司 Use of csf-1r kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021553A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
AU6998000A (en) * 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
MXPA02001152A (en) * 2000-06-01 2002-08-20 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene.
CA2423050A1 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
CN1703206A (en) * 2001-09-04 2005-11-30 泰姆斯多夫药品有限公司 Plaster for the treatment of dysfunctions and disorders of nail growth
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
BR0311172A (en) * 2002-05-13 2005-04-26 Children S Hospital Los Angele Treatment and prevention of abnormal scarring in keloids and other internal or skin lesions or injuries
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
JP4183193B2 (en) * 2002-08-30 2008-11-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Nitrogen-containing aromatic ring derivatives
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
PE20060664A1 (en) * 2004-09-15 2006-08-04 Novartis Ag BICYCLE AMIDAS AS KINASE INHIBITORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021553A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use

Also Published As

Publication number Publication date
MA29788B1 (en) 2008-09-01
MY145751A (en) 2012-03-30
JP2009507871A (en) 2009-02-26
EP1945217B1 (en) 2012-05-02
KR20080058376A (en) 2008-06-25
IL189984A0 (en) 2008-11-03
AR056194A1 (en) 2007-09-26
ECSP088259A (en) 2008-04-28
TNSN08112A1 (en) 2009-07-14
SG165371A1 (en) 2010-10-28
TWI325321B (en) 2010-06-01
EP1945217A2 (en) 2008-07-23
RU2424804C2 (en) 2011-07-27
BRPI0615881A2 (en) 2011-05-31
GT200600411A (en) 2007-05-21
WO2007031265A3 (en) 2007-07-12
US20120172386A1 (en) 2012-07-05
NZ566474A (en) 2011-05-27
NO20081807L (en) 2008-05-16
SA06270315B1 (en) 2010-12-21
CA2621399A1 (en) 2007-03-22
RU2008114048A (en) 2009-10-20
ATE555790T1 (en) 2012-05-15
WO2007031265A2 (en) 2007-03-22
PE20070457A1 (en) 2007-06-06
AU2006291526A1 (en) 2007-03-22
US20080306058A1 (en) 2008-12-11
TW200744600A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
US20120172386A1 (en) Combinations Comprising a VEGF Receptor Inhibitor
ES2401192T3 (en) Deazapurines useful as inhibitors of janus kinases
ES2911888T3 (en) Heteroaryl compounds as IRAK inhibitors and uses thereof
US9073916B2 (en) Prodrug forms of kinase inhibitors and their use in therapy
ES2660914T3 (en) 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as PHD inhibitors
ES2841452T3 (en) Pyridazinone macrocycles as IRAK inhibitors and their uses
ES2929424T3 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
ES2558780T3 (en) Imidazopyridazines as Akt kinase inhibitors
BR112018004175B1 (en) PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, HER2 INHIBITOR AND ANTITUMOR AGENT CONTAINING SAID COMPOUND AND THERAPEUTIC USES OF SAID COMPOUND
MX2010014029A (en) Heteroaryl compounds and uses thereof.
KR20220161396A (en) Preparation, Compositions, and Crystal Forms of Substituted Pyridinone-Pyridinyl Compounds
KR20090103897A (en) Pyrazolopyrimidine compound
JP2021502400A (en) Substituted pyrolopyrimidine JAK inhibitor and method for making and using it
MX2010008269A (en) Oxim derivatives as hsp90 inhibitors.
JP2022531088A (en) Substituted pyrolopyridine as a JAK inhibitor
ES2340664T3 (en) DERIVATIVES OF SULFONAMIDS.
CN108069939B (en) Compound containing conjugated dienamide structure, preparation method, pharmaceutical composition and application thereof
CN106458881A (en) Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof
ES2910839T3 (en) Pyridylpyridone compounds
ES2889100T3 (en) Methods of using trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
ES2910157T3 (en) Morpholinylpyridone compounds
EP2994127B1 (en) Furanone compounds as kinase inhibitors
CN101304747A (en) Contains a combination of VEGF receptor inhibitors and penetration enhancers
RU2799006C2 (en) ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND
HK40011485A (en) Inhibitors of the fibroblast growth factor receptor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired